Medicinal Chemistry 09 - UZH - Department of · PDF filewinter semester 09 Daniel Obrecht, Polyphor Ltd 1 Agenda Medicinal Chemistry: Combinatorial Chemistry-Parallel Synthesis 1

winter semester 09 Daniel Obrecht, Polyphor Ltd 1

AgendaMedicinal Chemistry: Combinatorial Chemistry-Parallel Synthesis

1. Introduction: The Drug Discovery Process

2. Lead Discovery and Lead Optimization-Drugability

-Drug-like molecules-the rule of 5-Drug-like vs lead-like: the rule of 3-Privileged scaffolds-Unwanted properties: frequent hitters-aggregate forming molecules

3. Combinatorial and Parallel Synthesis in Medicinal Chemistry

-Historical background-objective-Compound mixtures versus single compounds-Solid phase synthesis versus synthesis in solution

4. Combinatorial Synthesis of Biopolymers

-Polypeptides-Peptoids, Oligoureas, Oligocarbamates-Oligosaccharides-Oligonucletides, Oligonucleosides



4. Combinatorial synthesis of Biopolymers (cont.)

-Combinatorial synthesis-split-mixed synthesis-Tagging strategies

5. Strategies for the Synthesis of Small Molecule Libraries

-Library synthesis planning-Synthesis strategies-Classical multi-component reactions (MCR’s)-Sequential multi-component reactions (SMCR’s)-Fragment-based lead discovery-Dynamic Combinatorial Synthesis; Target-guided synthesis (TGS)

-Disulfide thethering-Click chemistry

-Building blocks-Parallel and/or combinatorial synthesis-Parallel work-up



6. Applications of Parallel Synthesis and Combinatorial Chemistry inMedicinal Chemistry: Case Studies

-Drug targets

7. Appendix (Definitions; Reviews; Literature)


The value added chain of pharmaceutical R & D

Medicinal Chemistry: Combinatorial Chemistry-Parallel Synthesis1. Introduction: The Drug Discovery Process

-From 1960 to 1980 the development time of a new NCE (new chemical entity) have quadrupled

-Since 1980 9-13 years have been necessary for the louching of a new drug

-Costs have gone up from 300-450 MioSFr (1987) to 600-800MioSFr in 2000

-Main reasons: higher degree of scientific knowledge of the drug required; regulations for clinical qualityassurance; change in the professional regulations of physicians; increase for administrative work for healthauthorities

-It is of prime importance to reduce the development time and costs for the development of a new NCE inorder to reduce the costs of new drugs while keeping the profitability: increase productivity of R & D

J. Kuhlmann, Int. J. Clinical Pharmacol. Ther. 1997, 35, 541-552



Medicinal Chemistry: Combinatorial Chemistry-Parallel Synthesis

Medicinalchemistry

Parallelchemistry

Targetidentification

Hitidentification

Hitexploration,hit-to-lead

Leadoptimization

Preclinicaland clinical

development

Screeninglibraries

Drug Discovery Process

Screeningcapabilities

ADMETproperties

Molecularmodeling

Genomics; Proteomics; Phage display,Fragment screening; X-ray crystallography

PEM, smallmolecules,fragments

Assaydevelopmentcapabilities

Establishingprimary

screening



5-12 m 12-36 months 3-6 m

Selecting Leads thatare “drugable”Avoiding problematictemplates

LeadOptimisation

Clinical Candidate Selection(CCS) from alternatives(Candidate Profiling)

Selecting the candidate that providesthe best exposure (e.g. unboundconcentration at target ) withoutsafety concerns

Of 10projects

starting inLead

Identification<3.5 willreachCCS(..but

5possible?)

Removingthe ADMETconcerns

A t t r i t i o n i n D i s c o v e r y

0 . 0 0

2 . 0 0

4 . 0 0

6 . 0 0

8 . 0 0

1 0 . 0 0

1 2 . 0 0

L e a d Id e n t i f i c a t io n L e a d O p t im is a t io n C C S

>30%30% >50%

30%


6-9 m 12m 24m

Phase 1 Phase 3EfficacyLong termSafety

Ensuring PK, metabolism, exposure,half-life,, safety, in humans are asexpected. Definition of possible humansafety issues and margins.Reproductive toxicity

Long term pre-clinical & clinical safety,carcinogenicity studies.Final assessment of drug-drug interactions &of bioavailability of the final marketedformulation

12-24m

Phase 2Proof-of-Concept

12-24m

RegulatoryApproval

A t t r it io n in D e v e lo p m e n t

0 .0 02 .0 04 .0 0

6 .0 08 .0 0

1 0 .0 01 2 .0 0

1 4 .0 01 6 .0 0

E IH E n a b lin g Ph a s e 1 P h a s e 2 Ph a s e 3 R e g is t r a t io n N D A

E IH E n a b l in g

P h a s e 1P h a s e 2

P h a s e 3R e g is t r a t io n

N D A

30%10% 40%*

20%62%*50%

45%*20%

13%*<5%

4% ofmarketed cpds withdrawn



Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis1. Introduction: The Drug Discovery Process

Metabolism

Liver

PortalVein

Gut WallGut

Lumen

Dissolution

Permeation

pH rangesstomach 1.5-6upper g.i. tractpH 4.4-7.8

colon 5effect of food,bile acids etc

Dose

Undissolveddose

Various TissuesBrain

SystemicCirculation

Renalexcretion of drugand/or metabolites

Tissuedistribution

MetabolismMetabolism and

biliary clearance ofunchanged drug

Metabolismand exhalation

by lung



Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis









Conc vs Time Curves

0

2

4

6

8

10

12

0 5 10 15 20 25 30Time (h)

Cm

g/L

C mg/L_Oral C mg/L_IV

Distribution &Elimination

Phase

t ½ = 6h, k =0.693/t1/2= 0.12h-1

Absorptionphase

t maxCmax

Cmin


bioavailability of drugs


AUC(injected)

AUC(oral)

Time

Plasma concentration

Drug injected

Drug given orally

Bioavailability =AUC (oral)

AUC (injected)


Drug-like molecules-the rule of 5

Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis2. Lead Discovery and Lead Optimization-Drugability

What is a drug-like molecule?

leading references: [1] C. Lipinsky et al. Adv. Drug Delivery Rev. 1997, 23, 2; [2] H. Kubinyi et al. J. Med.Chem. 1998, 41, 3325; [3] M. Murko et al. J. Med. Chem. 1998, 41, 3314; ¨[4] J. R. Proud-food, Bioorg. Med. Chem. Lett. 2002, 12, 1647

O N NO

N

O

F O

H

linezolid (antibiotic)

H-acceptor

H-acceptor

H-acceptor

H-donor

C15H18FN3O4 (323.33)

Lipinski's rules of 5:

-logP < 5-molecular weight < 500 (600)-not more than 5 H-bond donors-not more than 10 H-bond acceptors(or 10 hetero atoms)-not more than 5 (10) rotatable bonds

molecules which obey to Lipinski'srule of 5 have a high propensity forpenetration into cells and for oralabsorption


Drug-like molecules-rule of 5


Lipinski's rules of 5:

-logP < 5-molecular weight < 500 (600)-not more than 5 H-bond donors-not more than 5 H-bond acceptors(or 10 hetero atoms)-not more than 5 (10) rotatable bonds

molecules which obey to Lipinski'srule of 5 have a high propensity forpenetration into cells and oral absorption

NH

HN

NH

HN

O

O

O

O

NH2

HN

H2N NH2 x Cl-

OO

OH

OH

+

C17H30N808 x HCl (511.03)

Ac-RGDSNH2 (fibrinogen antagonist)

MG: ok; logP < 5 (ok); 13 H-donors (violation); 16 hetero atoms (violation); 17 rotatable bonds (violation)

-peptides, proteins, oligonucleotides and oligosaccharides in general show violations of Lipinski's rules;

-these molecules have many H-bond donors and acceptors, which in physiological environment are surroundedby water molecules. They show generally low cell penetration, low passage through the blood brain barrierand low oral absorption. In addition these molecules are generally quickly degraded by various enzymes, whichcan also be an advantage.

-these molecules have to be administered by a topical, i.p. or i.v. route; in recent years significant progress hasbeen made in administering biomolecules: liposomes, inhalation methods, direct injection techniques into the brain..


privileged fragments


O

OH N N

N

N O NH

N

POH

OH

O

NMR based screening of fragments binding towards a variety of proteins:Bcl-2 (an antiapoptotic protein), stromeolysin (MMP), VEGF-RBD, p56lck SH2,FK-506 BP and others.S. W. Fesik et al. J. Med. Chem. 2000, 43, 3443-47


Lead-like: the rule of 3


The properties of 40 fragment hits identified against a range of targets usinghigh throughput X-ray crystallographic screening technology has been examined.The results indicated that on average fragment hits possessed properties consistentwith a rule of three:

-MW <300-Number of H-bond donors <3-Number of H-bond acceptors <3-clogP =3

In addition it was noted that:

-The number of rotatable bonds was on average <3-Polar surface area was <60A2

M. Congreve et al. Drug Discov. Today 2003, 8, 876-77; M. Hann, T. I. Oprea, Curr. Opin. Chem.Biol. 2004,8, 255-263


unwanted properties: frequent hitters


In order to exclude as early as possible compounds with undesired properties fromcompound libraries several selection criteria (filters) have been developed:

-chemically reactive compounds: alkylating agents, Michael acceptors etc.(G. M. Rishton, Drug Disc. Today, 1997, 2, 382-4)-toxic chemical groups (toxophores)-oral bioavailability-aqueous solubility-metabolic clearance-frequent hitters:(O. Roche et al. J. Med. Chem. 2002, 45, 137-142)

-the activity of the compound is not specific for the target (promiscuous)-the compound perturbs the assay or detection method (coloured orfluorescent molecules)-molecules prone to form polymers (e.g. catechols)-molecules have a high tendency to form aggregates


unwanted properties: reactive groups


Reactive compounds and in vitro false positives in HTS ( G. M. Rishton, Drug Disc. Today, 1997, 2, 382-4)

RS

X

O O

sulfonyl halides (X: Cl, Br)

R X

O

acyl halides (X: Cl, Br)

R X

alkyl halides (X: Cl, Br, I)

R

O

O

O

R'

anhydrides

N

NX

halopyrimidines

R H

O

aldehydes

R R''

N

imines

R'

R

O

-halo-ketones (X: Cl, Br)

XR'O

O

aliphatic esters

R R'

O

aliphatic ketones

RF3C

trifluoro-ketones

R

O

R R'

N

R R'

R'' R'S

O

aliphatic thioesters

R

epoxides aziridines

R'OS

sulfonate esters

RO O

R'OP

phosphonate esters

RO O

R

O

O

R'

1,2-dicarbonyl compounds

RO

OR'

RS

SR'

RO

SR'

RN

SR'

R''

RN

OR'

R''

RN

NR'

R''

Hheteroatom-heteroatom single bond

R

O

R' R

O

OR' R

O

NR'R''

Michael acceptors

O


unwanted properties: frequent hitters


O. Roche et al. J. Med. Chem. 2002, 45, 137-142

OH

HO

diethylstilbestrol (1.00)

examples of frequent hitters (Matthew correlation coefficient: >0.8)

HOOH

NH2

dopamine(0.88)

NN

ClN

HN

Cl

clofazimine(1.00)

HN

OH

HO

OH

OH

fenoterol(0.87)

molecules that form aggregates

NN

NN

NH2

SO3H

NH2

SO3H

non-drug-like

NH

O

SS

N

CO2H

S

Cl

Cl

drug-like

G. Müller, Drug Disc. Today, 2003, 8, 681-91


privileged structures


A single framework or fragments which can bind to different target families in aspecific way

The term privileged structure was first used by Evans et al. (J. Med. Chem. 1988, 31, 2235-46) on the development of potent, selective, orally active cholecystokinin antagonists

The benzodiazepin scaffold was the first scaffold termed as privileged. It occurs in valium,librium, in CCK-A antagonists and several more.

N

N

Cl N

N

N

O Me O

NH

O HNO

F

F

N

NMe O

F NH

Valium




O

O

SO O

COX-II inhibitor (Vioxx)

N

N

N N

NH2

F

p38 MAP kinase (SB-218655)

NS

NH

Cl

Me

Cl

dopamine transporter inhibitor

non-planar arrangement of two aromatic rings avoids stacking

Privileged structures include often favorable conformational arrangements of aromatic/heteroaromatic groups. Planar arrangements of aromatic groups give raise to stackingWhich results in unfavorable properties such as low solubility and aggragation.




N

SNH2

N

SNH

OH

CBS-113A (clinical)COX, 5-lipoxygenase

N

SN

S

ON

NH

OHOH

O

H

BMS-268770 (discovery)CDK-2 inhibitor

N

SN

H

HN

N

CP-146662 (discovery)5-HT1A agonist, dopamine uptake

N

SNH2

N

Cl

Cl

CGS-2466(discovery)Adenosin A3 antagonist,PDE-4, p38 MAP kinase

N

SN

HO2N

SO

O

OMe

OMe

Ro 61-8048 (discovery)Kynurenin-3-hydroxylase

amino-thiazole scaffold




NH

2-aryl-indole scaffold

NH

NO

N

OMe

Br

NK1 antagonist (0.8nM)

NH

5-HT6 (0.7nM)5-HT7 (0.3M)

N

Br

NH

HN

B r

CCR5 (1.3M)CCR3 (0.9M)

C. A. Willoghby, Biiorg. Med. Chem. Lett. 2002, 12, 93-6


Questions


1. What are the Lipinski‘s rules of five and what do they stand for?

2. Please determine number of rotatable bonds, number of H-bonddonors and acceptors of the following molecules?

COOH

O

O

OHO

HOHO

OH

COOH

A B

H-Lys-Glu-NH2

C

N

N

Cl

O

D

3. Describe the difference between drg-like and lead-like


3. Combinatorial and Parallel Synthesis in Medicinal ChemistryMedicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis

1961: Ivar Ugi publishes his pioneering paper on his four component reaction: “If, for example, 40 of each differentcomponents are reacted with one another, the result is 2‘560‘000 raction roducts...“

R1COOH

R2NH2

R3CHO

R4N=CR1

O

NR2

R3

O

NHR4Ugi 4MCR1

2

3

4

NR3

R2

C NR4

R1 O-

O

H+

NN

R3

OO

R1R4

R2

H+H

R1

O

NR2

R3

O

NHR4irreversible


1963: Seminal paper by R. B. Merryfield describing for the first time the successful synthesis of a short peptideon a polystyrene resin (J. Am. Chem. Soc. 1963, 85, 2149)

1965: Letsinger and Khorana applied solid supports for the synthesis of oligonucleotides (J. Am. Chem. Soc. 1965,87, 2149); J. Am. Chem. Soc. 1966, 88, 3181)

1967: J. Fréchet described a highly loaded trityl resin (2.0mmol/g)

1967: Wilkinson et al. Described polymer-bound tris-(triphenylphoshine)chlororhodium as a hydrogenation catalyst(J. Am. Chem. Soc. 1967, 89, 1574)

1969: Solid-phase synthesis of Ribonuclease (J. Am. Chem. Soc. 1969, 91, 501)

1970: H. Rapoport introduced the term hyperentropic efficacy (effect of high dilution) on solid supports(J. Am. Chem. Soc. 1970, 92, 6363)

1971: Fréchet et al. pioneerd solid-phase synthesis in the field of carbohydrate research (J. Am. Chem. Soc. 1971,93, 492)

1973: Application of intramolecular Dieckmann-condensation for the solid-phase synthesis of lactones by Rapoportet al. (J. Macromol. Sci. Chem. 1973, 1117)






1973: Leznoff et al. described the use of polymer-supports for the mono-protection of symmetrical dialdehydes,oxime-

formation, Wittig reaction, crossed aldol formation, benzoin-condensation and Grignard reaction(Can. J. Chem. 1973, 51, 3756)

1974: F. Camps describes the first synthesis of benzodiazepines on solid support (Ann. Chim. 1974, 70, 1117)

1976: Leznoff and Files described bromination and lithiation of insoluble polystyrene, thus pioneering the synthesisof

functionalized resins (Can. J. Chem. 1976, 54, 935)

1976: Rapoport and Crowley published a review entitled: Solid-phase organic snthesis: novelty or fundamentalconcept?

which raised three important questions: -degree of separation of resin-bound functional groups; -analyticalmethods to follow reactions on solid support; -nature and kinetics of competing side reactions

(Acc. Chem. Res. 1976, 9, 135)

1976-1978: Leznoff et al. published a series of papers dealind with the synthesis of insect sex attractants (Can. J. Chem..

1977, 55, 1143)

1977: Wulff et al. Synthesized chiral macroporous resins using carbohydrates as templates for the use of columnmaterials for the separation (Makromol. Chem. 1977, 178, 2799)



O


1979: Leznoff employed successfully a chiral linker for the assymetric synthesis of (S)-2-methyl-cyclohexanone in 95%e.e. (Angew. Chem. 1979, 91, 255)

1974: F. Camps describes the first synthesis of benzodiazepines on solid support (Ann. Chim. 1974, 70, 1117)

1984: Geysen et al. described the the multi-pin technology for the multiple peptide synthesis (Proc. Natl. Acad. Sci.USA, 1984, 81, 3998)

1985: Houghten et al. described the tea-bag method for multiple peptide synthesis (Proc. Natl. Acad. Sci. USA, 1984,81, 3998)

1985: G. P. Smith described in seminal paper the use of filamentous phage for the synthesis of peptide libraries(phage display method, Science 1985, 228, 1315)

1986: Mixtures of activated amino acid monomers were coupled to solid supports for the synthesis of peptide librariesas mixtures; the product distribution depended on the relative couplind rates (Mol. Immunol. 1986, 23, 709)

1991: Fodor et al. described the VLSIPS method (very large scale immobilised polymer synthesis; photolitographicparallel synthesis (Science 1991, 251, 767)




1991: Almost simultaneously Furka et al. described the `portioning-mixing‘ method (Int. J. Pept. Prot. Res. 1991,37, 487); Hruby et al. the `split synthesis‘ (Nature 1991, 354, 82); and Houghten et al. the `divide, coupleand recombine`process (Nature 1991, 354, 84)

1992: Oligonucleotide-encoded chemical synthesis by Lerner and Brenner (Proc. Natl. Acad. Sci. USA, 1992, 89, 5181)

1992: Synthesis od 1,4-benzodiazepines on solid support described independently by S. Hobbs-DeWitt (Diversomertechnology, US-Pat. 5324483, 1993) and J. A. Ellman (J. Am. Chem. Soc. 1992, 114, 10997)

1993: Binary encoded synthesis using gas chromatographically detectable chemically inert tags by W. C. Still et al.(Proc. Natl. Acad. Sci. USA, 1992, 89, 5181)

1993: Use of multi-cleavable linkers for the synthesis of peptide-like libraries by M. Lebl et al. (Int. J. Protein Res.1993, 41, 201)

1994: Use of the `safety-catch` linker principle developed by Kenner et al. (J. Chem. Soc. Chem. Commun. 1973, 636)by J. A. Ellman for multidiretional cleavage from the resin (J. Am. Chem. Soc. 1994, 116, 11171)

1995: Synthesis of a potent ACE inhibitor by combinatorial organic synthesis on solid support using a 1,3-dipolarcycloadddition reaction by Gallop et al. (WO 95/35278, 1995)




1995: Use of a genetic algorythm for the selection of the products of an Ugi four component reaction (Angew. Chem.Int. Ed. Engl. 1995, 34, 2280)

1996: Use of the Ugi four component reaction in combination with a 1,3-dipolar cycloaddition reaction of intermediaryformed `Munchnones` with electronpoor acetylenes by R. Armstrong et al. (Tetrahedron Lett. 1996, 37, 1149)

1997: Combination of a cyclo-condensation reaction, multicomponent diversification and multidirectional resin cleavageusing a novel `safety-catch -̀ and traceless linker yielding highly diverse pyrimidines by D. Obrecht et al. (Chimia1996, 11, 530; Helv. Chim. Acta 1997, 80, 65) and L. M. Gayo et al. (Tetrahedron Lett. 1997, 38, 211)

1997: Synthesis of a taxoid library using radiofrequency-encoding (J. Org. Chem. 1997, 62, 6092)

2001: Click Chemistry: Diverse Chemical Function from a few good reactions: H. C. Kolb, K. B. Sharpless, Angew.Chem. Int. Ed. 2001, 40, 2004-21; ibid Drug Discovery Today 2003, 8, 1128-37.

2001: Dynamic Combinatorial Chemistry: J. M. Lehn et al. Science 2001, 291, 2331-32.

2001: Using an enzyme‘s active site to template inhibitors: R. Nguyen, I. Huc, Angew. Chem. Int. Ed. 2001, 40, 1774

2005: Receptor-assisted Combinatorial Chemistry: Thermodynamics and Kinetics in Drug Discovery: J. D. Cheesemanet al. Chem. Eur. J. 2005, 11, 1708-16

2006: In situ click chemistry: a powerful means for lead discovery: B. K. Sharpless et al. Expert Opin. Drug Discov.2006, 1(6), 525-38




2004: Fragment-based drug discovery: D. A. Erlanson, R. S. McDowell, T. O‘Brien, J. Med. Chem. 2004, 47, 3463-3482; D. C. Rees, M. Congreve, R. Carr, Nat. Rev. Drug Discov. 2004, 3, 660-672.


The role of combinatorial chemistry and parallel synthesis in drug discovery

Chemical Biology: Combinatorial Chemistry-Parallel Synthesis3. Combinatorial and Parallel Synthesis in Medicinal Chemistry

Large Screening Librariesfor High Throughput Screening

100'000 to 3'000'000 compounds

Aim:

-Hit confirmation, validation and exploration of SAR

Methods:

-High throughput parallel synthesis in solution

Focused Libraries forHit Confirmation and Validation

100 to 1'000 compounds

Aim:

-Hit identification

Methods:

-Combinatorial synthesis on solid support-High throughput parallel synthesis in solution

Focused Libraries forHit-to-Lead Optimization20 to 100 compounds per cycle

Aim:

-Hit optimization, SAR, ADMET properties, TPP

Methods:

-Medicinal chemistry approaches; parallel synthesis


Chemical Biology: Combinatorial Chemistry-Parallel Synthesis3. Combinatorial and Parallel Synthesis in Medicinal Chemistry

Compound mixtures:

-Mixtures (most often 10-20 compounds) of purified compounds in equimolar amounts

-Mixtures of products synthesized in one reaction in equimolar ratio:Mol. Immunol. 1986, 23, 709

(Boc)FmocHN

R

O

OH

H2N

R1-20

O

O

R1-20: coding amino acidsratio determined according

to coupling rates

(Boc)FmocHN

R

O

HN

R1-20

O

O

-Most often products originating from a reaction mixture are not formed in equimolar ratio arecontaminated with impurities

Advantage: compound mixtures can reduce the screening effort in expensive and laborious screens

Drawbacks: compounds in mixtures can interfere with one another; prone to false positive hits

Trend today: screening of single compounds


3. Combinatorial and Parallel Synthesis in Medicinal ChemistryChemical Biology: Combinatorial Chemistry-Parallel Synthesis

Single compounds:

-Synthesis on solid supports without final purification:requires a lot of development work; allows to make large libraries

-Synthesis in solution using high yielding reactions without further purification:limits the scope of reactions that can be used; often used in the context of multi-component reactions; useful for large libraries

-Synthesis in solution followed by high-throughput preparative HPLC-purification:whole repertoire of organic reactions can be used; is todays standard method forthe synthesis of focused libraries (hit validation; lead optimization)

Trend: as screening technologies have increased the throughput, screening of single compoundlibraries is more and more becoming the standard

as companies are looking for highly diverse general compound libraries of high quality(purity, stability) library synthesis has shifted from solid phase synthesis (large libraries)to solution phase synthesis followed by high-throughput purification (normal andreverse phase)



Chemical Biology: Combinatorial Chemistry-Parallel Synthesis

Solution phase chemistry:

++ most reactions and reagents have been studied in solution

+ usually no excess of reagents have to be used

+ solvent effects can be studied and altered readily

++ steric effects are usually less pronounced in solution and can be overcome more easilyby using more drastic reaction conditions

++ reaction conditions are usually adapted to a large variety of substituents

-- extensive and time consuming, chromatographic purification procedures are oftennecessary

-+ side products have to be separated and analysed (can also be an advantage in the firstexploratory stage of a given project

-- parallelisation and automation usually requires more initial effort




Solid phase chemistry:

++ excess of reagents can be used to drive reactions to completion

++ purification procedures achieved by simple filtrations which can be easily automated

++ assuming complete spatial separation of the reactive sites on a given solid support, theprinciple of high dilution („hyperentropic effect“, Acc. Chem. Res. 1976, 9, 135) can beused beneficially; e.g. for intramolecular cyclisation reactions

+- overall costs for the synthesis of large libraries (assuming no purification of the finalcompounds is necessary) can compare favourably with solution synthesis

+- linker molecules have to be designed which are compatible with the polymeric matrix andthe chemistry used for library synthesis: labour intense development work; ok for largelibraries

-- development of reaction conditions requires more work than in solution reactions on solidsupport are more sensitive to steric effects: limitations in the design of highly diverselibraries

-- reactions are more difficult to monitor; especially a drawback in the development phase


Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis3. Combinatorial and Parallel Synthesis in Medicinal Chemistry

General trends:

Solid-Phase chemistry: large libraries (no purification of individual compounds)

split mixed approach

linear approaches: polypeptidespeptoidsoligosaccharidesoligocarbamates and ureas

use of solid support as a protective group: for guanidines, amidines, hydroxamicacids, carboxylic acids, alcohols..)

Solution-phase chemistry: small focused libraries of high chemical diversity (purified products)

parallel synthesis

convergent approaches

General


Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis3. Combinatorial and Parallel Synthesis in Medicinal Chemistry

Questions

1. What are the advantages of using mixtures of compounds in thebiological screening?

2. What are the disadvantages?

3. What are the advantages of using solid phase chemistry?

4. For which type of molecules is it advantageous to use solid phasechemistry?


Examples for libraries synthesized on solid-phase: linear approaches

Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis4. Combinatorial Synthesis of Biopolymers

Monomer A1 Monomer A2 Monomer A3 Monomer A4

bond bond bond bond bond

monomers

amino acids

nucleotides

mono- and disaccharides

N-alkylated glycines

bond formation

amide bond

phosphorester bond

glycosidic bond

amide bond

polymers

peptides, proteines

oligonucleotides

polysaccharides

peptoids


Examples for libraries synthesized on solid-phase: peptides


-Peptides synthesized as individuals or as mixtures on solid supports (polystyrene, polyacrylamide,polyacrylamide-polystyrene co-polymers) and cleaved to be assayed in solution

-Peptides synthesized and assayed as individuals or as mixtures on solid supports such as pins (H. M.Geysen et al. Mol. Immunol. 1986, 23, 709), resin beads (K. S. Lam et al. Nature 1991, 354, 82), cotton(R. A. Houghton et al. Biochemistry 1993,32, 11035), microchips (S. P. A. Fodor et al. Science 1991, 37, 481),or cellulose membranes (A. Kramer et al. Pept. Res. 1993, 6, 314)

-Peptides synthesized on the surface of a filamentous phage: Phage display technology(G. P. Smith et al. Meth. Enzymol. 1993, 217, 228; J. K. Scott et al. Curr. Opin. Biotechnol. 1994, 5, 40)

Mixtures of peptides can be obtained by by using two different strategies:

-As true mixtures where a peptide coupling step involves the coupling of a mixture (typically the 20coding amino acids) of side-chain protected Boc- or Fmoc- protected amino acids (D or L) in apredetermined molar ratio which compensates for the different coupling rates.

-as mixtures of resin beads which resulted from synthesis: òne bead-one compound concept``portioning-mixing` (A. Furka et al. Int. J. Protein Res. 1991, 37, 487)`couple and recombine` (R. A. Houghton et al. Nature 1991, 354, 84)`split synthesis` (V. Hruby et al. Nature 1991, 354, 82)


solid-phase peptide synthesis: overview


FmocHN

R

O

OH

BocHN

R

O

OH

FmocHN

R

O

O(NH) Linker Polymer

P1

P2

P1

FmocHN

R

O

O Linker Polymer

P1

FmocHN

R1

O


P1-cleavage, wash

NH

R1

O


PO

H2N

R2P

NH

R1

O


PO

HN

RP

OH2N

Rn+1P

n

NH

R1

O

OH(NH2)

PO

HN

RP

OH2N

Rn+1P

n

NH

R1

O

OH(NH2)O

HN

ROH2N

Rn+1

Fmoc-strategy

Boc-strategy

-coupling, wash-cleavage, wash 1 cycle

n cycles


solid-phase peptide synthesis: resins-polymer supports


FmocHN

R

O

OHFmocHN

R

O


P1 P1

Fmoc-strategy

1. Functionalized polystyrene resins:

+Ph

Ph

Ph

Ph

Ph

Ph

cross-linked polystyrene resin(1-2%)

+

(1-2%)FG

Ph

Ph

Ph

FG

FG

randomly functionalized cross-linked polystyrene resin

+

selectively functionalized cross-linked polystyrene resin

FG: CH2X (X: Cl, OH, NH2)

*

*

* suspension polymerisation: water, free radical catalyst (dibenzoyl peroxide, AIBN), dispergator: particle size dependsupon stirring speed, the relative amounts of aqueous and monomer phases, amount and nature of dispergator




OMe

styrene, DVB OMe

Cl

i

Cl

styrene, DVB ii

styrene, DVB

(up to 2.5 mmol/g loading)

1. Functionalized polystyrene resins

Ph

ClPh

PhCl

(95:5 para/ortho)

microporous: 1-2% crosslinking

macroporous: 20% crosslinking

chloromethyl-polystyrene resin (Merryfield resin: J. Am. Chem. Soc. 1963, 85, 2149)

i: BCl3, CCl4, 0°, 2h; ii: NaOH, CHCl3 (or ClCH2CH2Cl), BnN+Et3, Cl-, SO2Cl2, AIBN, 60°; Macromolecules 1986, 19, 2470




Swelling properties of Merryfield type microporous resins:

Solvent crosslinked PS (1% DVB)* crosslinked PS (2% DVB)*

MeOH 0.95EtOH 1.05 1.0AcOH 1.0MeCN 2.0pyridine 3.0DMF 3.5 2.0THF 5.5dioxane 4.9 2.5Et2O 2.6CH2Cl2 5.2toluene 5.3 2.8

*swelling capacity: volume of swollen resin/original volume


solid-phase peptide synthesis: linkers


i: ethylene oxide; ii: propylene oxide, SnCl4, CH2Cl2; iii: ethylene oxide, KOH, dioxane, 110°

2. TentaGelR resins

Bayer and Rapp; Angew. Chem. Int. Ed. Engl. 1991, 30, 113; contain up to 60-80% of PEG units

OHCH2O(CH2CH2O)3CH2CH2O-K+ CH2O(CH2CH2O)4+nH

i

OH

Me

O(CH2CH2O)nH

Meii ii i

Good swelling properties in: water, MeOH, CH2Cl2, MeCN, THF and DMF; used preferentially in continous flow reactors

3. Polyacrylamide resins

pioneerd by Sheppard: Bioorg. Chem. 1979, 8, 351

O

N

O

NH

HN

O

basic monomer crosslinking agent

O

NH

HN

O

NHBoc

functionalized monomers

O

N CO2Me

Persulphate initiated copolymerisationin 66% aqueous DMF, 1,2-dichloroethane and cellulose acetate/butyrate as emulgator


solid-phase peptide synthesis: linkers


2. Linkers for releasing carboxylic acids

structure abbreviation cleavage conditions reference

Cl

OH

O

OH

O

OH

OMe

O

OH

OMe

OMe

Ph

ClCl

Merryfield resin HF, CF3SO3H J. Am. Chem. Soc. 1963, 85, 2149

hydroxymethyl-PS HF, CF3SO3H

Wang resin 95% TFA J. Am. Chem. Soc. 1973, 95, 1328

SasrinR resin (Bachem) Tetrahedron Lett. 1988, 29, 40051% TFA

Rink resin 1% TFA Tetrahedron Lett . 1987, 28, 3787

Tetrahedron Lett. 1989, 30, 3943chloro-trityl resin(Barlos)


Solid-phase peptide synthesis: linkers


2. Linkers for releasing amides

structure abbreviation cleavage conditions reference

O

O

NH2

OMe

OMe

HF, CF3SO3H J. Org. Chem. 1985, 50, 5291BHA (R=H)MBHA (R=Me)

Rink resin 95% TFA

PAL resin Int . J. Prot. Pept. Res. 1987, 30, 206TFA

TFA

Tetrahedron Lett. 1987, 28, 3787

NH2

RPeptides. 1981, 2, 85

O

OMe

OMe

NH2

O

OMeNH2

Tetrahedron Lett. 1997, 38, 7325

O

NOH

NO2

Kaiser oxime resin NH3 J. Org. Chem. 1980, 45, 1295

primary and secondary aminesNH2NH2 x 1H2O



HOOC NHFmoc HOOC NHFmoc

H Me

HOOC NHFmoc

H

HOOC NHFmoc

H

HOOC NHFmoc

H

HOOC NHFmoc

H

OH (Boc)

HOOC NHFmoc

HOH (tBu)

HOOC NHFmoc

HOH (tBu)

HOOC NHFmoc

H

SMe

HOOC NHFmoc

H* *

HOOC NHFmoc

H

N(Boc) H

HOOC NHFmoc

HCOOH (tBu)

HOOC NHFmoc

HCONH2 (NHTr)

HOOC NHFmoc

H

COOH (tBu)

HOOC NHFmoc

H

CONH2 (NHTr)

HOOC NHFmoc

H

NN

(Tr) H

HOOC NHFmoc

H

HOOC NHFmoc

HSH (Tr)

NH2 (Boc)

HOOC NHFmoc

H

HN

NHPbf

NH

HOOC NHFmoc

HS

2

glycine; Gly; G alanine; Ala; A valine; Val; V leucine; Leu; L phenylalanine; Phe; F

serine; Ser; S threonine; Thr; T methionine; Met; M isoleucine; Ile; I tyrosine; Tyr; Y

aspartic acid; Asp; D aparagine; Asn; N glutamic acid; Glu; E glutamine; Gln; Q tryptophan; Trp; W

lysine; Lys; K arginine; Arg; R cysteine; Cys; C cystine; Cys2; histidine; His; H


Solid-phase peptide synthesis: coupling reagents


NN

N

ONMe2, X-

NMe2

+

X-: PF6- HBTU; BF4

- TBTUTetrahedron Lett. 1989, 30, 1927

N NN

N

ONMe2, X-

NMe2

+

X-: PF6- HATU

NN

N

O PNMe2, X-

NMe2

+

X-: PF6- , BF4

-, (Castro's reagent)Tetrahedron Lett. 1975, 1219

NMe2

X P NN

N+

,PF6- (X=Cl, PyCloP)(X=Br, PyBroP)J. Org. Chem. 1994, 59, 2437

PhOPPhOO

N3 DPPA (diphenyl-phosphoryl azide)

N C N R2R1

R1=R2= iPr (DIC)R1=R2=cyclohexyl (DCC)R1=Et; R2=CH2CH2N

+Me2, Cl- (EDCI)

uronium salts

carbodiimides

azides

Y NN

N

OH

, Y= CH, N

acid fluorides

R-COOH

N N

NF F

F

baseR-COF

R-COOHbase

R-CON3

J. Chem. Soc., Chem. Commun. 1994, 201


Solid-phase peptide synthesis: protective groups


Fmoc strategy: Cleavage

Main chain (backbone) amino groups: Fmoc 20% piperidine/DMF, rt

Side chain amino groups (Lys, Orn, Dab): Boc TFA, CH2CH2, triisoprpoylsilane*

Side chain carboxylic acids (Glu, Asp): t-butyl esters TFA, CH2CH2 triisopropylsilane*

Side chain primary amides (Gln, Ans): N-trityl TFA, CH2Cl2, triisopropylsilane*

Side chain hydroxy(phenol) groups (Ser, Thr, Tyr):t-butyl ethers TFA, CH2Cl2, triisopropylsilane*

Side chain indole and imidazole groups (Trp, His): N-trityl TFA, CH2Cl2, triisopropylsilane*

Side chain guanidine groups (Arg): Pmc, Pmb TFA, CH2Cl2, triisopropylsilane*

*other scavengers like thioanisolphenol, H2O, thiocresol and othersare used


Examples for libraries synthesized on solid-phase: peptoids


Peptoids: ideal scaffold for parallel and combinatorial synthesis

NH

HN

R1

O R2NH

O R3

Opeptide backbone

NN

ON

O

OR1

R2

R3

peptoid backbone

-protease stability increased

-number of H-bond donors reduced (can be also disadvantage)

-number of rotatable bonds increased (tertiary amides have lower trans-cis barrier)

-prediction of peptoid backbone conformation quite difficult (flexibility)

-ideally suited for library synthesis: large number of building blocks availableavailable by solid-phase synthesissplit-mixed synthesis possible

NH

NHN

N

R1

O R2NH

ONR3

O

azapeptide backbone




Approach A: sequential coupling of N-substituted glycines

NH

ONR1

Fmoc

i, iiNH

ONR1

ONR2

FmocH2N

ONR1

ONR2

ONR3

H

Approach B: sequential coupling of glycine followed by reductive amination with aldehydes

NH

ONH

Fmoc

iii, ivNH

ONR1

H NH

ONR1

ONH

Fmocv

NH

ONR1

ONR2

HH2N

ONR1

ONR2

ONR3

H

iii, iv

i: DBU, DMF; ii: PyBop or PyBrop, R2NFmocCH2COOH; iii: DBU, DMF; vi: RCHO, Na(OAc)3BH or NaCNBH3, MeOH; v: Fmoc-Gly,PyBop or PyBrop; vi: DIC, DMF, BrCH2COOH; vii: R-NH2, DMSO




Approach C: coupling of bromo-acetic acid followed by nucleophilic displacement with amines

NH2 NH

OBrvi

NH

ONR1

Hvii

NH

ONR1

ONR2

Hvi, vii

H2N

ONR1

ONR2

ONR3

H

i: DBU, DMF; ii: PyBop or PyBrop, R2NFmocCH2COOH; iii: DBU, DMF; vi: RCHO, Na(OAc)3BH or NaCNBH3, MeOH; v: Fmoc-Gly,PyBop or PyBrop; vi: DIC, DMF, BrCH2COOH; vii: R-NH2, DMSO

Proc. Nat. Acad. Sci. USA 1992, 89, 9367

HNO

N

O

O

CONH2

OHChir 4531

Screening 18 pools originated from split-mixed synthesisfor [3H]-DAMGO (-specific) binding to opiate receptor.Chir 4531: 6nM


Examples for libraries synthesized on solid-phase: oligosccharides


OO O

PhN3

S

OHHO

OO O

Ph N3

S

OHO

O

OPiv

PivOOPiv

SPh

OPivO

OO O

N3

S

OO

OOPiv

PivOOPivPivO

Ph

OO O

N3

OH

OO

OPiv

PivOOPivPivO

Ph

O

SO

OBnBnO

BnO

OO O

N3

S

OO

Ph

O OBnBnO

BnO

OO O

N3

OH

O

Ph

O OBnBnO

BnO

i

ii ii

ii i iii

i: Cs2CO3, Merryfield resin; ii: Tf2O, 2,6-di-tert-butyl-4-methylpyridine, CH2Cl2, -60 to -20°; iii: Hg(OCOCF3)2, CH2Cl2, H2O, r.t.

D. Kahne et al. J. Am. Chem. Soc. 1994, 116, 6953; ibid J. Am. Chem. Soc. 1994, 116, 1766; ibid J. Am. Chem. Soc. 1989, 111, 6881


Questions


1. Name at least three different types of solid supports?

2. Give at least two different ways to synthezise chloro-methyl polystyrene?


Drug-like molecules-the rule of 5


What is a drug-like molecule- how are drugs adminstered

Topical administration:

-intra-, trans- and extradermal: sprays, ointments, powders, plasters-inhalation: sprays, powder inhalators

Subcutaneous administration:

-by syringes; special devices (slow release)

Intravenous (i.v.):

-injections (syringes) of solutions of the drug into venes (blood-stream)

Intraperitoneous (i.p.):

-injections (syringes) in the peritoneous

Oral (parenteral):

-formulation of the drug into various forms of pills; absorption through themucosa into the blood stream

type of molecules

small molecules (<600)peptides, proteins (antibodies,fusion proteins) and others

especially well suited forproteins (e.g. antibodies)



small molecules (<600)


Examples for libraries synthesized on solid-phase: parallel synthesis of single compounds


H2N

R1

O

O H2N

R2

O

O

FmocHN

R1

O

OH

NH

R1

O

OO

H2N

R1NH

R20

O

OO

H2N

R1

NH

R1/2

O

OOH

N

R1-20O

R1-20

H2N

800 products

NH

R1

O

OO

HN

R1O

R1

H2N

R2 R3 R10 R20FmocHN

R1

O

OH

NH

R2

O

OO

H2N

R1NH

R2

O

OO

H2N

R20

R2 R3 R10 R20

40 times couple and cleave

40 individual products

FmocHN

R1

O

OH R2 R3 R10 R20FmocHN

R1

O

OH R2 R3 R10 R20

40 times couple and cleave

NH

R20

O

OO

HN

R1O

R20

H2N NH

R2

O

OO

HN

R1O

R1

H2N NH

R2

O

OO

HN

R20O

R20

H2N

800 individual products

40 reaction vessels

800 reaction vessels


Examples for libraries synthesized on solid-phase: parallel synthesis of mixtures


H2N

R1

O

O H2N

R2

O

O

FmocHN

R1

O

OH

NH

R1

O

OO

H2N

R1NH

R1

O

OO

H2N

R20

NH

R1/2

O

OO

HN

R1-20O

R1-20

H2N

800 products

NH

R1

O

OOH

N

R1O

R1

H2N

R2 R3 R10 R20FmocHN

R1

O

OH

NH

R2

O

OO

H2N

R1NH

R2

O

OO

H2N

R20

R2 R3 R10 R20

2 times couple* and cleave

mixture of 20 products

FmocHN

R1

O

OH R2 R3 R10 R20FmocHN

R1

O

OH R2 R3 R10 R20

NH

R1

O

OOH

N

R20O

R20

H2N NH

R2

O

OO

HN

R1O

R1

H2N NH

R2

O

OO

HN

R20O

R20

H2N

mixture of 20 products

mixture of 400 productsmixture of 400 products

2 times couple* and cleave

*cocktail of 20 amino acids

2 reaction vessels


Examples for libraries synthesized on solid-phase: one bead-one compound


H2N

R1

O

OH2N

R2

O

O

mix

divide

H2N

R1

O

OH2N

R2

O

O

Pool 1 Pool 2

couple, cleave couple, cleaveFmocHN

R1

O

OH

H2N

R1

O

OH2N

R2

O

O

NH

R1/2

O

O

Pool 1 (2 products)

OH2N

R1

FmocHN

R2

O

OH

NH

R1 /2

O

O

Pool 2 (2 products)

OH2N

R2

Pool 3 Pool 20

NH

R1/2

O

OO

HN

R1-20O

R1-20

H2N

800products

FmocHN

R20

O

OH

Pool 2O (2 products)

mix

divide

Pool 1 (40 products)

NH

R1/2

O

OO

HN

R1-20O

R1

H2N

Pool 2 (40 products)

NH

R1 /2

O

OOH

N

R1-2 0O

R2

H2N

NH

R1/2

O

OO

H2N

R20

Pool 20 (40 compounds)

NH

R1/2

O

OOH

N

R1-20O

R20

H2N




Parallel synthesis of compound mixtures:

++ high-throughput with little synthetic manipulations-- difficult interpretation of screening results (synergistic and non-synergistic effects)-- resynthesis of individual compounds necessary

generally not used anymore

Parallel synthesis of single compounds

++ clear screening results++ identification of structure unambiguous++ resynthesis generally not necessary; repurification required-- many parallel synthetic steps and reaction vessels required; usually expensive robotic equipment

requiredmethod of choice for relatively small compound libraries

Split mixed synthesis of mixtures (one bead- one compound):

++ usually clear screening results can be obtained; on bead or in solution++ large libraries with few synthetic steps can be obtained in real combinatorial fashion-- only small amounts are usually obtained and structure of hits have to be determined by cleavage

and MS or deconvolution or tagging (binary codes or radio-frequency labels) startegiesmethod of choice for large combinatorial libraries




Parallel synthesis of single compounds

-tea bags: e.g. R. A. Houghton et al. Proc. Natl. Acad. Sci. USA.,1985, 82, 5131; G. Jung et al. Pept. Res. 1991, 4, 88

-multi pins: H. M. Geysen et al. Proc. Natl. Acad. Sci. USA.,1984, 81, 3998

label

resin beads (up to 100mg)

polypropylene netSpatially separated reaction compartments, where peptides canbe synthesized by capitalizing on the fact that all washing,neutralisation and deprotection steps can be performed simulta-neously. For parallel synthesis the bags are separated beforethe coupling steps.

96 wells96 pins

polyacrylic acid-grafted polyethylene

Spatially separated parallel synthesis of compoundsin microtiter format


Examples for libraries synthesized on solid-phase: peptides: photolithography


NO2

O

O

HN COOH

R' R

OO

XnH2N

OO

XnHN

O

R

NH

O

O

NO2

R'

h

OO

XnHN

O

R

H2N

NO2

CHOR'

96 well formathhh

h

Photolithography: light-directed combinatorial synthesis (S. P. A. Fodor et al. Science 1991, 251, 767)

Spatially separated multiple parallel synthesis using photocleavalbe protective groups such as the N-nitro-veratrylcarbonyl group (NVOC), allows the controlled synthesis of (peptide) libraries by the spatially controllableaddition of specific reagents to specific locations.


Questions


1. What are the advantages of a split-mixed approach over a parallelsynthesis approach and for which types of molecules will you applythis technology? Please discuss.


Examples for libraries synthesized on solid-phase: peptides: split-mixed technology (one bead-one compound)


NH

RA-G

O

OOH

N

RA-GO

RA-G

H2N

73= 343 tripeptides

OA NHFmocO

OB NHFmocO

OC NHFmocO

OD NHFmocO

OE NHFmocO

OF NHFmocO

OG NHFmocO

mixcleavesplit

step 2

Pool 1A

Pool 1B

Pool 1C

Pool 1D

Pool 1E

Pool 1F

Pool 1G

HOO

X NHFmoc

A

B

C

D

E

F

G

couple

OX1 NHO

OX2-NHFmoc

Pool 2A (7)

Pool 2B (7)

Pool 2C (7)

Pool 2D (7)

Pool 2E (7)

Pool 2F (7)

Pool 2G (7)

dipeptides

mixcleavesplit

Pool 3A (49)

Pool 3B(49)

Pool 3C (49)

Pool 3D (49)

Pool 3E (49)

Pool 3F (49)

Pool 3G (49

A

B

C

D

E

F

G

couple, cleave

Pool 4A(49)

Pool 4B (49)

Pool 4C (49)

Pool 4D (49)

Pool 4E (49)

Pool 4F (49)

Pool 4G (49)

tripeptides

step 3

342 tripeptideson bead

step 1

OX1 NHO

OX2-NH

OX3-NH2




Iterative deconvolution (Nature 1991, 354, 84; Science 1994,266, 2019; Proc. Nat. Acad. Sci, USA 1993, 90, 10811)

Sreening reveals in which of the Pools 4A to 4G are the most active compounds; determines most active building blockin the 3rd step (position): assumption it is B; Pools 2A to 2G are resynthesized but not mixed and coupled with buildingblock B in the third step. The compounds are retested and this determines the favoured building block in the secondstep (position): assumption it is G. Now the initial 7 resins are coupled with G (2nd step) and B (3rd step) and the resultingCompounds tested again. The most active tripeptide is now identified: assumption it is A-G-B.

Recursive deconvolution (e.g. Nat. Acad. Sci, USA 1994, 91, 11422)

By using this technique samples of the initial resins as well as Pools 2A-2G and Pools 4A-4G are stored away forresynthesis of sublibraries similarly to the iterative deconvolution procedure.

Positional scanning (e.g. Nat. Acad. Sci, USA 1994, 91, 11422; Life Sci. 1993, 52, 1509)

Indexed or orthogonal libraries (e.g. Chem. Biol. 1995, 2, 621; Tetrahedron Lett. 1997, 38, 491)

Binary encoding (e.g. W. C. Still et al. Proc. Nat. Acad. Sci, USA 1993, 90, 10922)

Radio-frequency tags (Irori system): (J. Am. Chem. Soc. 1995, 117, 10787; J. Org. Chem. 1997, 62, 6092)


6.5. Examples for libraries synthesized on solid-phase: peptides: split-mixed technology : binary encoding


Binary encoding(e.g. W. C. Still et al. Proc. Nat. Acad. Sci, USA 1993, 90, 10922)

NH

RA-G

O

OO

HN

RA-GO

RA-G

H2N

73= 343 tripeptides

7 building blocks

3 steps

requires 9 tags

GC/MS

step 1 step 2 step 3

1 2 3 4 5 6 7 8 9

step 1: building block A: 1 0 0 tag 1B: 0 1 0 tag 2C: 0 0 1 tag 3D: 1 1 0 tags 1 + 2E: 1 0 1 tags 1 + 3F: 0 1 1 tags 2 + 3G: 1 1 1 tags 1 + 2 + 3

step 2: building block A: 1 0 0 tag 4B: 0 1 0 tag 5C: 0 0 1 tag 6D: 1 1 0 tags 4 + 5E: 1 0 1 tags 4 + 6F: 0 1 1 tags 5 + 6G: 1 1 1 tags 4 + 5 + 6

step 3: bui lding block A: 1 0 0 tag 7B: 0 1 0 tag 8C: 0 0 1 tag 9D: 1 1 0 tags 7 + 8E: 1 0 1 tags 7 + 9F: 0 1 1 tags 8 + 9G: 1 1 1 tags 7 + 8 + 9

NO2

O

O

O OArn

O

Ar:

Cl Cl

Cl Cl

Cl Cl

Cl

n: 0-x variations of Ar and n gives rise to the different tags,which can be detected in minute amounts by GC/MS

for tripeptide E-C-G:

GC/MS

step 1 step 2 step 3

1 3 6 7 8 9

1 0 1 0 0 1 1 1 1


Examples for libraries synthesized on solid-phase: peptides: radio-frequency tags


Radio-frequency tags (Irori system): (J. Am. Chem. Soc. 1995, 117, 10787; J. Org. Chem. 1997, 62, 6092)

resin beadsfret

radio frequency tag (code)

Irori can (polypropylene)code A

codeB

codeC

codeD

codeE

codeF

codeG

mix

A

C

D

E

F G

B

couple B

cleave

sort(radio frequencyreader)

AB

CB

DB

EB

FB GB

BB




Application of the split-mixed method for discovery of Factor Xa inhibitors

Factor Xa is implicated in the blood coagulation cascade: inhibitors of Factor Xa couldbe potentially useful as anti-thrombotic agents(Biochemistry 1998, 37, 1053-1059; Drug Discovery Today 1998, 3, 223))

H-Tyr-Ile-Arg-Leu-Ala-Ala-Phe-Thr-NH2 (SEL1691) O

NH O

HN

O

NH

HN

O

O

N

O

NH2

N+HN

NH2 X-

SEL2602

octa-peptide library (split-mixed technology)

on-bead screening





Blood coagulation factor Xa is implicated in hemostasis (bloodcoagulation)

Thrombosis: pathological form of hemostasis: myocardial infarction (arterial thrombosis)pulmonary embolism (venary thrombosisinfection by gram-negative organisms

XII XII

XI XIa

IX IXa

intrinsic pathways

Factor X

Factor Xa

VIIa VII

extrinsic pathways

Prothrombin Thrombin

Fibrinogen

Fibrin

cross-linked fibrin clot

XIIIa

Factor Xa inhibitors

Thrombin inhibitors

/Va/Ca2+

VIIIa/Ca2+ TF*/Ca2+

*tissue factor


6.5. Examples for libraries synthesized on solid-phase: peptides: split-mixed technology (one bead-one compound)



Current anti-thrombotic therapies include: aspirin

Thrombin inhibitors: heparin (sulphated poly-saccharide); heparin analogues; hirudin; small molecularweight thrombin inhibitors (not on the market yet)

high levels of thrombin inhibition necessary; unacceptable bleeding

Factor Xa inhibitors: trypsin-like serine protease

current molecules in clinical trials

SHN

NH

NH2HN

O O

O

O

NH

NH

NH2HN

OS

N

Cor-Therapies (IC50 factor Xa: 0.65nM)(IC50 thrombin: 10.0M)

H2N

NH

NS COOH

O

N

NHOO

Yamanouchi (IC50 factor Xa: 1.3nM)(IC50 thrombin: >100M)





Synthesis of a octa-peptide library by split-mixed synthesis and colorimetric assay on bead:

Factor Xabiotinylated

Factor Xa biotin

Streptavidin-AP

Streptavidin-AP

Factor Xa biotin

biotin

biotinbiotin Factor XA

Factor Xa

Factor Xa

complex

inhibitor

inhibitorinhibitor

inhibitor

AP: alkaline phosphatase

AP: alkaline phosphatase de-phosphorylates 5-bromo-4-chloro-3-indolyl phosphate forming a blue precipitate,which stains the beads





Synthesis of a octa-peptide library by split-mixed synthesis and colorimetric assay on bead:

All active compounds contained Tyr-Ile-Arg at the N-terminus

O

NH

O

HN

OH

O

NH

HN

O

HN

HNNH2

O

N

O

NH2

H-Tyr-Ile-Arg-Leu-Ala-Ala-Phe-Thr-NH2 (SEL1691; IC50: 4-15M))

O

NH

O

HN

NH2

O

NH

HN

O

HN

HNNH2

O

N

O

NH2

SEL2316 (IC50: 80nM) SEL2489 (IC50: 25nM; half-life inrats and rabbits 8 to 10 minutes)

Drug Discovery Today 1998, 3, 223





O

NH O

HN

OH

O

NH

HN

O

HN

HNNH2

O

N

O

NH2

O

NH O

HN

NH2

O

NH

HN

O

HN

HNNH2

O

N

O

NH2

SEL2316 (IC50: 80nM) SEL2489 (IC50: 25nM; half-life inrats and rabbits 8 to 10 minutes)

O

NH

O

HN

NH2

O

NH

HN

O

O

N

O

NH2

SEL2602 (IC50: 285nM)

N+

O

NH

O

HN

O

NH

HN

O

O

N

O

NH2

N+HN

NH2 X-

SEL2602 (IC50: <25nM; improved half-life)


Examples for libraries synthesized on solid-phase: peptides: thrombin inhibitors)


Application of solid-phase chemistry for discovery of thrombin inhibitors

R

N ON

O Fmoc

R

N ON

OO

NHBoc

PhPh

NO

O

NH2 x TFA

PhPh

R1HNi, ii iii, iv

NO

O

NH2 x TFA

PhPh

Cl

Cl

IC50: 3nM

i: 20% piperidine, DMF; ii: amino acid, HBTU, HOBt, DIEA, DMF;iii: R1NH2, DMF; iv: TFA

J. Med. Chem. 1998, 41, 401-406; J. Med. Chem. 1998, 41, 1011-1013

multi-directional cleavage


Examples for libraries synthesized on solid-phase: inhibitors of protein-protein interaction


•Fundamental to the functioning of biological systems–many proteins function as part of complexes–cell to cell signalling–cell adhesion–long distance communication (hormones)

•Specific inhibition offers important therapeutic potential:

•Generally form across a large area of interacting surfaces: 700-1300 A2 average•High binding energy•Difficult to inhibit with small molecules? Small molecule discovery approaches have largely failed•Antibodies and fusion proteins (biopharmaceuticals) have emerged as important drugs:however, these act only on extracellular targets

•Slow to mature : initial binding is thought to occur through “hotspots” in selected areas

Characteristic of large surface protein-protein interactions


6.5. Examples for libraries synthesized on solid-phase: inhibitors of protein-protein interaction


average contact surface area in protein-protein interactions: 600-900 A2

Hotspots

O-Rings

topology of the hotspots determine specificity

Bogan, A. A.; Thorn, K. J. Mol. Biol. 1998, 280, 1-9

°




growthhormone

ExtracellularGH-receptor

Wells, PNAS, 1996, 93, 1-6; Science, 1995, 267, 383

Kd 0̃.3 nMBuried surface on each protein˜1300 Å2


•~40% of all HTS campaigns in GSK were targeted to find small PPI inhibitors in 1998•Very low success rate•Many assays suitable for HTS developed

•Most were “shelved” during portefolio review•Addressed one important target with full resource



Petidic -helix mimetics as inhibitors of protein-protein interactions

Dr. Sjoerd Wadman




Oncostatin M

-4-Helical Cytokine

-Pro-inflammatory hormone

-Therapeutic applications:

-Rheumatoid Arthritis

-Asthma

-Interacts with 7TM receptor

-Part of a large family of important proteins


Examples for libraries synthesized on solid-phase: four helix bundle proteins


Long Chain4-helix bundle

Short Chain4-helix bundle

Dimeric-dimeric4-helix bundle

Family

Growth HormoneProlactin

IL-6IL-3IL-7LIF

OSMCNTFCDF

IL-2IL-4

IL-13IFN-aIL-5

GM-CSFM-CSF

IL-10IFN-GIFN-B







Note side-on interactions of -helices




--helices cluster with hydrophobic residues poiting atthe inside (red) whereas hydrophilic residues (yellow)are located at the outside

-challenge:inhibit formation of 4-helix bundle formation byinteracting with the helical momomers




-Helix side-chains are arranged like the steps on aspiral staircase

-Regular distance

-Regular angle

-Model potential antagonists and pick the ones thatfit the model best

-Aimed to antagonise “side-on” -helixinteractions through 3 side-chains

-Large - 100k compounds

-Non-peptidic

-Split - mix synthesis on solid phase

-Fully Encoded / Partial Release Technology

-384 screening format




CORE 1 CORE 2

FG1 FG2 FG35-7 angstrom 5-7 angstrom

LINK1

LINK2

LINK3

1-14 1-14

1-7 1-7

Amino acid-like side-chains

Spacers hold side chains in correct orientation




Propose Connectivityand potential monomers

Model compoundsproposed library

Measure fit againstHelix Vector Model

Take best connectivityand best monomers




Core 1N

N

H

Core 2N

NH

O

H

O

O

H

R1R2 R3

O

Amines

14

4

Amino acids

7

3

-Amino acids

14

4

Amino acids

7

3

Amines

14

3Tagsrequired

Total number of compounds: 134'456




amines

NH2NH2

NH2NH2

H2NNH2

O

H2N

O

NH2 ONH2

TrONH2

neutral

acidic

O

O

NH2 O

O

NH2

basic

N NH2 N

N

NH2 NBoc NH2 BocHN NH2


6.5. Examples for libraries synthesized on solid-phase: four helix bundle proteins


Core 1 amino acids

NHFmocHOOC

H H

NHFmocHOOC

H

H

NHFmocHOOC

H

H

NHFmocHOOC

H

H

NHFmocHOOC

H

H

NHFmocHOOC

OMeOMe

NHOOC Fmoc




-Amino acids

HOOC NHFmocHOOC NHFmoc HOOC NHFmoc HOOC NHFmoc

HOOC NHFmoc HOOC NHFmoc

OtBu

H H H

H HHOOC NHFmoc

HOtBu

HOOC NHFmoc

HOtBu

HOOC NHFmoc

H

MeS

HOOC NHFmoc

HCOOtBu

HOOC NHFmoc

H

COOtBu

HOOC NHFmoc

H

HNNBoc

NHBoc

GlyAla

ValLeu

Phe Tyr

Ser Thr

Met

Asp

Glu

Arg

Hyp (hydroxyproline)




Core 2: Diacids (Anhydrides)

O

O

O

O

O

O

H

H

O

O

O

H

H

O

O

O

O

O

O

H

H

O

O

O

O

O

O

H

H

O




Major conformers closely match -helix in side-chain display vectors

N

O

H

HN O

Me N

H

ON

COOH

H

O




Concepts

-Split Mix synthesis

-Library encoding

-Differential release

-Single Bead screening

Mix

Mix

3 building blocks3 products in pools of 1

9 products in pools of 3

27 products in pools of 9

1 bead = 1 compound




Building BlocksCodes foreach building block




O

N

ONH

N

ONH

O

NH

O N

ONH alloc

Linker

-Codes are different amines-Cleaved with cHCl-Dansylate and analyse by hplc

Product on acid-or photolabile linker

Affimax encoding strategy




Differential release

CODE

NH

ONH

OO

NO2

OMe

NH

ONH

OO

OMe

Product

ACID-LABILE LINKER

PHOTO-LABILE LINKER

50% on acid labile linker50% on photolabile linker

Product can be releasedtwice at different times




Single bead screening

Cleave Tag from bead

Screen poolsAcid cleave

Active pool

Active bead

Identify active molecule

Plate out individual beadsphotocleavescreen single beads




Single bead screening

-Compounds prepared on Tentagel

-Reactions done on an ACT synthesis robot

-All building blocks were “rehearsed”

-Analysis throughout

-1st stage by magic angle nmr

-later stages by lc/ms and tag reading

-lc/ms aided using “analytical constructs”

-All done by one chemist in 5 months




Resin differentiation

Amino Tentagel

BocNHOH

O

FmocNHOH

O

10:1

NH2NH2

NH

ONHBoc

NH

OFmocNH

DIC, HOBT, DMF

1 10

NH

ONHBoc

NH

ONH2

DIPEA, DMF

NH

ONHBoc

NH

ONH

ON

Aloc

Code 1

NOH

O

O

O

Code1

NH

ONH2N

H

ONH

ON

Aloc

Code 1

95%TFA

NH

ONH

Photolinker

NH

ONH

ON

Aloc

Code 1

DIPEA, HATU, DMF

DIPEA, HATU, DMF

PhotolinkerAcid Linker

NH

ONH

AcidLinker




Prepared resin




Reductive amination

NH

ONH

OO

O

NO2

OMe

NH

CODE

NH

ONH

OO

O

OMe

NH

ONH

OO

NH

NO2

OMeNH

CODE

NH

ONH

OO

NH

OMe

NH2

Me4NBH(OAc)3

AcOH, DMF




Library synthesis 1NH

CODE LinkerN

O

NHFmoc

MeO

MeO

CODE Linker1)Split/mix

OMeOMe

O

OH

NHFmoc2)

HATU,DMF,DIPEA1) Split/mix2) Code deprotection3) Codecoupling4) Fmoc deprotection5) HATU,DIPEA,DMF

NHFmocO

OH

CODE Linker

NHFmocO

O

N

OMeO

MeO

CODE Linker

NHO

O

N

OMeO

MeO

OO

OH

1) Split/mix2) Code deprotection3) Codecoupling4) Fmoc deprotection5) Pyridine

O

O

O




Library synthesis 2

CODE Linker

NHO

O

N

OMeO

MeO

OO

OH

CODE Linker

NHO

O

N

OMeO

MeO

OO

NH

O

OtBu

1) Split/mix2) Code deprotection3) Codecoupling4) pyridine, DMF

FF

F

FF

O

O

F

F

F

5) DIPEA, DMF

NH2 OtBu

O


6.5. Examples for libraries synthesized on solid-phase: four helix bundle proteins


Final construct

HN

O HN

O

O

MeO

N

O HN

OHN

OO N

H

CO2t-Bu

OMe

OMe

NO2

HN

O

NH

O

O

N

O HN

O

NH

OO

HN

CO2t-Bu

OMe

OMe

OMe

NH

OHN

N

O

NH2

O

O

N

O

N

O O

NH2

NH2

O

NN

NH2

O

O

NH2

O

O

O

HN

O HN

O HN

OO N

H

OMe

OMe

CO2H

EBMP

C3C4

BBMH'BP

MoPPHH

C3C10MdD oO'O'

OOPDDD

TARGET[542.6]

CONSTRUCT

acid-labile

photo-labile

tag

C27H34N4O8




Screening of library

•Primary screen :168 x 96 wells / ~30 beads per well

• 42 plates in 384 format

• Half of acid-cleaved material used

• Screening concentration ~ 2mM/component

Histogram of 1ry screening data for GL1495 in OSM

0

500

1000

1500

2000

-20

-15

-10 -5 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 10

010

5Mor

e

% Inhibition

Freq

uen

cy




Screening results

-21 sub-micromolar hits re-made as discretes

-5 Compounds potent and selective

-17 also inhibit TNF in same cell line : signalling inhibitors?

GSK compound collection

Natural product extracts

Aptamers

Apha helix library GL1495

250.000

70.000

2000.000

134.456

3134

18

78

21

0

0

13

5

Source Number Hits Leads




Acknowledgements

-Chemistry: Helen Jenkins

-Biology: Paul Life, John Spaul

-Screening: Liz Clarke, Sandra Arpino

-Modelling: Darren Green

+ many others

And Dr. Sjoerd Wadman


Examples for libraries synthesized on solid-phase: peptides: phage display


The native phage contains a DNA genomesurrounded by a protein coat. At one end of thephage are 5 copies of the Gene3 gene productexpressed from the phage genome.

Gene3 protein

The phage infects a host bacterial cell (e.g. E.Coli) and uses the bacterium to replicate itself,leading to secretion of progeny phage.

In phage display, the E. Coli host contains aDNA plasmid encoding Gene3 fused to either aprotein of interest, or a library of randompeptides. As the phage replicates, Gene3 fusionproteins (expressed from the plasmid) areincorporated into the phage coat. Libraries ofphages can be produced, with each bacteriumproducing phages with a unique peptidedisplayed at its surface determined by theplasmid (the phage also contains the at thispoint) of the host cell.

plasmid

E. coli

G. P. Smith et al. Meth. Enzymol. 1993, 217, 228; J. K. Scott et al. Curr. Opin. Biotechnol. 1994, 5, 4)


Examples for libraries synthesized on solid-phase: peptides: Phage display panning techniques


A library of phages, eachdisplaying a unique peptidesequence, is allowed to bind toa plate coated with the targetmolecule (e.g. protein).

Unbound phages are washedaway.

Specifically bound phages areeluted.

After 3-4 rounds of panning, individualphage clones are isolated and sequencedto determine the sequence of the displayedpeptide.

The eluted phages areamplified and panningprocess is repeatedseveral times.


Examples for libraries synthesized on solid-phase: phage display


Functional mimicry of a protein hormone by a peptide agonist: EPO receptor complex; Science 1996, 273, 464-471

Erythropoetin (EPO) is the primary hormone that regulates the proliferation and differentiation of immature erythroidcells. Recombinant human EPO is widely used in the treatment of patients with anemia due to renal failure, cancerchemotherapy, and AZT treatment. The EPO receptor belongs to the cytokine receptor superfamily, which includesreceptors for other hematopoetic growth factors, such as interleukins (IL) and colony-stimulating factors (CSF), as wellas growth hormone (GH), prolactin, and ciliary neurotrophic factor (CNTF).

Screening of a phage libray (Annu. Rev. Microbiol. 1993, 47, 535) against immobilized EPOR gave an activeconsens sequence, and a very potent member of the family with agonistic activity in vitro and vivo was identified (seeFigure).

Y

SS

KPQG C

CS

V W

FHT

H2N

G

G Y G

P

L

T

G

COOH



Polyphor2001-1/JPO/DO



Chemical strategies used for the synthesis of small molecule libraries: overview

Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis5. Strategies for the Synthesis of Small Molecule Libraries

1. Planning (literature search and retrosynthetic analysis of the problem)

Steps required for the design and synthesis of a library

3. Building blocks (commercial or self-made)

2. Synthesis strategy (linear, convergent, multicomponent reactions, tandem reactions...)

5. Parallel work-up (two phases: aqueous, organic, fluoruos; solid-phase extraction)

7. Analysis, stability and storage of products

4. Parallel or combinatorial synthesis (in solution; in solution by aid of solid-supported reagents; onsolid supports)

6. Purification: parallel flash chromatography; high-throughput HPLC coupled to MS on normal andreversed phase


Synthetic strategies: introduction


N

NHN

R2

HN

O

R3

R1

scaffold

low variation substituents

scaffold: MG~290; for the substituents remain MG~210

high variation substituents

N

NHN

R2

HN

O

R3

R1

scaffold

high variation substituents low variation substituents

diversity associated with scaffolds: "vertical diversity"; diversity associatedwith substituents: "horizontal diversity"

the synthetic strategies generally do not permit simultaneous high variationof substituents R1-R3; rather sub-libraries (e.g. A and B) are planned; alsoSAR data often show that not all substituents are equally importantfor biologicalactivity

exit vectors: determine the relative orientation of the highand low variation substituents and thus the overall shapeof the final molecule

sub-library A

sub-library B


Synthetic strategies: convergent, multi-step


NH

O

O

O

R1 R1

N

N

OR2

Cl

R1

N

N

OR2

NHR2

building blockfinal products

Multi-step synthesis of advanced building blocks (scaffold) by linear or convergent syntheticstrategies and parallel conversion into final products


Synthetic strategies: classical multi-component approach


R1NH

NH2

R2N=C=S

R3

OBr

+

+N

S

R3

R1N

R2

O HN

S

R3

R1N

R2

O

OR4

building blocks final products

Synthesis of advanced building blocks (scaffold) using multi-component reactions andparallel conversion into final products


Classical multi-component reactions


A B C+ +

A

B CA B C

intermèdiaire

- Classical multi-component reactions (MCR‘s) are have in common that components (e.g. A, B, C) react ina reversible way to a reactive intermediate, which reacts in a irreversible way to the product. Thus, thesequence by which the components are added does nor affect product formation.

- The best known MCR‘s are the following: Ugi, Passerini, Biginelli, Strecker, Hantzsch, Mannich etc.

- Reactions can be ideally performed in a matrix format

- Classical MCR‘s generally yield generally the same scaffold




R1COOH

R2NH2

R3CHO

R4N=CR1

O

NR2

R3

O

NHR4Ugi 4MCR1

2

3

4

NR3

R2

C NR4

R1 O-

O

H+

NN

R3

OO

R1R4

R2

H+H

R1

O

NR2

R3

O

NHR4irreversible

The classical multi-component reactions are ideally suited for parallel synthesis, however, theyyield generally the same scaffold (limited scaffold diversity)




R1COOH +R2

O

R3+ R4N=C R1 O

O

O

HN

R4

R2 R3

Passerini 3-MCR

H. Passerini, Gazz. Chim. Ital . 1921, 51, 126

RCHO + NH3 + HCNR CN

NH2

Strecker synthesis

Bucherer-Bergs variation of the Strecker synthesis

KCNR1

O

R2 + + (NH4)2SO4NH

NHR1

R2

O

O

A. Strecker, Justus Liebigs Ann. Chem. 1854, 91, 345; ibid. 1890, 23, 1474

H. T. Bucherer et al. J. Prakt. Chem. 1934, 140, 69; ibid. 1934, 140, 28


Mechanism of the Passerini 3-MCC reaction


R1COOH R2CHO R3N=C

R1

O

O

R2

O

NHR3Passerini 3MCR

OR2

C NR3

R1 O-

O

H+

NO

R2

OO

R1R3

H+

R1

O

O

R2

O

NHR3irreversible

A B C

reactive intermediate

H




R1 CHO

O

+ R2N=C + PhS COOHS

NPhSNHR2

R1

Modified Passerini 3-MCR

R. Bossio et al. J. Chem. Res. 1991, 15, 320O

NH4+HCO3

-

PhSO

OO R1

NHR2

O

NH4+HCO3

-

PhSO

OH2N R1

NHR2

OS

HNPhSNHR2

R1

OHO




Hantzsch MCR's

R1 NH2

S

+ R2 R3

O

Br

S

N

R1

R2

R3

R1N NH2

S

+ R2 R3

O

Br

S

N

R1N

R2

R3

R1 COOR2O

+ NH3 +R3 X

O

NH

R3R1

COOR2

R1 COOR2O

+ NH3 + R3-CHO

NH

R1R1

R2OOC COOR2R3

2 x

A. Hantzsch, Ber. Deutsch. Chem. Ges. 1890, 23, 1474


Classical MCR’s


R1 NH

O

COOH + Ac2O + R2CHOO

NR1

O

R2

Erlemeyer azlactone synthesis

NaOAc

R1 CHO

O

+ HN

MeOOC+ N

O

O

N

MeOOC

NOO

O

R1

R. Grigg et al. Tetrahedron 1993, 49, 8679

3-MCR involving a ü1,3¨-dipolar cycloaddition

N

MeOOC

OR1

+

-+ N

O

O




R2 COOR3O

H2N NH2

O+ R1CHO + HN

NH

O

R1

COOR3

R2

Biginelli 3-MCR

R3 COOR4O

R1S NH2

NH+ R2CHO + N

NH

R1S

R2

COOR4

R3

Biginelli 3-MCR (Atwal variation)

P. Biginelli, Ber. Deutsch. Chem. Ges. 1893, 26, 47; ibid. 1891, 24, 2962

Mannich 3-MCR

R1HN

R2 + CH2O +R3

R4 O

R5R3

R4 O

R5

NR1

R2R1

HN

R2 + CH2O +NH N

H

NR1

R2

C. Mannich et al. Arch. Pharm. 1921, 250, 647

;


Classical MCR’s


COOH

NH2

+

CHO

+HN

H

H

COOH

Grieco's 3-MCR

COOH

N

[4+2]

N

H

H

COOH

H

P. Grieco et al. Tetrahedron Lett. 1988, 29, 5855; R. W. Armstrong et al. Tetrahedron Lett. 1997, 38, 6163

R1 R2 + R3 R4+ CO R3

R4 R2

R1O

Pauson-Khand MCR

U. I. Khand et al. J. Chem. Soc. Perkin Trans. 1 1973, 9, 977


Classical multi-component reactions: applications


MeCOOEt

O

+ NH3 +NH

EtOOC COOEt

CHONO2

2 x

NO2

Nifedipine (AdalatR, Bayer)

MeCOOEt

O+

CHONO2

O

EtOOCNO2

MeCOOEt

O+ NH3

H2N

COOEt

1

2

1

N

EtOOCNO2

COOEt

- Nifedipine is a widely used anti-hypertensive drug (is off patent now). It belongs to the Ca2+ channel blockers(other include: Verapamil-type, Dilthiazem-type)

-It can be produced in a Hatzsch-type 3-MCR in a very efficient and cheap way.

Applications of MCR's


Application of the Ugi 4-MCR: genetic algorithm


R3NH2 + R1N=C

R4 OH

O+

R2 H

O

R4 N

O

R3

NHR1R2

O

+ NH

NHR1R2

O

R3+ +

L. Weber et al. Angew. Chem. Int. Ed. Engl. 1995, 34, 2280

Genetic algorithms constitute an interesting approach for effic ient optimization of multiparameter systems

Parameters: inputs acids, isocyanates, aldehydes, amines; biological activity (inhibition of thrombin)

Genetic operations: replication, mutation and crossover

SHN

ON

O

OH

OO

H2N NH2 x HCl

SHN

ONH

OO

H2N NH2 x HCl



R3NH2 + R1N=C

R4 OH

O+

R2 H

O

R4 N

O

R3

NHR1R2

O

+ NH

NHR1R2

O

R3

+ +

L. Weber et al. Angew. Chem. Int. Ed. Engl. 1995, 34, 2280

1 (10)3 (10)

4 (40)

5 (160'000)

2 (40)

0010 011100 0111 010011

1 2 3 4

H2N

H2N NH H2N NH

NH2

H2N NH

NH2

H2N NH

H2N

N N

O

NH2

NH2

NH2

HN

H2N NH

NH2

+ 4 amines

bit pattern

1st generation: random selection of 20 bit patterns: synthesis

2nd generation: generated by entering first 20 bit patterns into the genetic algorithm which by means of crossover andmutations generated the next 20 bit patterns: synthesis and biological testing of all 40 compounds

3rd generation: the 20 most active compounds (bit patterns) were again entered into the genetic algorithm which generatedthe next generation: synthesis and testing

after 16 cycles, the average effective inhibitory concentration (EC50) of the 20 best compounds was submicromolar

0010 011100 0110 110011

1 2 3 4

0011 011100 0111 010111

1 2 3 4

crossover mutation


Application of the Asinger-Ugi 6-MCR: Penicillin derivatives


OHC CO2Me

NO OPht

Br CHO

+ NaSH NH3+1. Asinger

2. hydrolysis

Br CHO HS CHO CO2Me

NHPht

SOHC

H2N

CO2H

NHPht

S

N N

SPhtN

O

ONHC6H11

C6H11N=C

*

*

HN=C CO2Me

NPht

*

N

S

NPht

O-

O

C N C6H11

HN

S

OO

PhtN

N H

C6H11


Questions


1. Please name three classical multi-component reactions (MCR‘s)?

2. Give possible products of the following MCR‘s

NO2

COOH+

CHO

+

NH2

+

N=C:

a)

b)

NH2

Cl+

S CHO+

MeOH

50°

CF3COOH

CH2Cl2


Sequential multi-component reactions


A BC

+ A B A B C

A CB

+ A C A C B

C BA

+ C B C B A

intermediate

- In sequential multi-component reactions (SMRC‘s) components (e.g. A, B, C) are added in a sequential way tothe reaction mixture. Thus, reaction of A + B form irreversibly intermediate A-B which is subsequently reactedwith C to form the product A-B-C. By changing the sequence of component addition theoretically 6 differentproduct types (scaffolds) can be obtained.

-The SMCR‘s offer the same advantages as the classical MCR‘s, but in addition they have the potential to gene-rate different scaffolds.




R1NH

NH2

R2-N=C=S

R3

OBr

N

S

R1 NHR2

+ +

N

NR1

R3

+ 2 x C

N

NR1

R3

+ +A B

C

A B C

O

R3

NHR2S

A C B

A

R3

O

N

N

N

R1

OR2

SO

R3

+A + CDI +B C

Sequential multi-component reactions (MCR‘s) offer the same advantages as the classical MCR‘s: inaddition several different scaffolds can be obtained employing the same set of building blocks

D. Obrecht, P. Ermert, 5th Ineternational conference on Synthetic Organic Chemistry (ECSOC-5); www.mdpi.org/ecsoc-5/,September 1-30, 2001, [B0005]




R S

NH2

NHR1

R S

NH2

NHNH2

R S

NH2

NHN

H2N

S

NHR1

H2N

S

NHNH2

H2N

S

NHN

Cl

O

N C O

BrO

R2

R4

O R5

HOO

R3

R7 N C S

R8 N C O

R9 X R10 NH2

OH

R6

OCOOMe

bis-donors bis-acceptors acceptor-donors electrophiles nucleophiles

+, X-

+, X-

+, X-

1

2

3

4

5

6

7

8

10

9

12

13

(X: Cl, Br, I)

(X: Cl, Br)

14

15

11





N

R'HN N

O

R'' N

R'HN N

O

R''RN

R'HN N

O

R''

R

N

R'HN N

R

N

R'HN N

R

R''N

R 'HN N

R

N

N

NNH

HO

NH

Ph

N

N

Me

Olomoucin

R





S

NH2

NHR

SMCR N

S N

OR''

R

S

NH2

NHR

SMCR N

S N

O

R''

RRR

N

NH

N

O

R''

R

R'

+X-

+X-

solid-phase

solution




R S

NH2

NHR1

R S

NH2

NHNH2

R S

NH2

NHN

H2N

S

NHR1

H2N

S

NHNH2

H2N

S

NHN

Cl

O

N C O

BrO

R2

R4

O R5

HOO

R3

R7 N C S

R8 N C O

R9 X R10 NH2

OH

R6

OCOOMe


+, X-

+, X-

+, X-

1

2

3

4

5

6

7

8

10

9

12

13

(X: Cl, Br, I)

(X: Cl, Br)

14

15

11




S

NH2

NH2

R4

O R5S N

N

R4

R5 NH

N

N

R4

R5R'

NH

N

NN

+, X-

4

10

+i ii , iii

i: DIPEA, DMF; ii: m-CPBA, CH2Cl2; iii : R'NH2 (15), dioxane, 80-100° [8].

O N

O





R S

NH2

NHR1

R S

NH2

NHNH2

R S

NH2

NHN

H2N

S

NHR1

H2N

S

NHNH2

H2N

S

NHN

Cl

O

N C O

BrO

R2

R4

O R5

HOO

R3

R7 N C S

R8 N C O

R9 X R10 NH2

OH

R6

OCOOMe


+, X-

+, X-

+, X-

1

2

3

4

5

6

7

8

10

9

12

13

(X: Cl, Br, I)

(X: Cl, Br)

14

15

11




R S

NH2

NHR1 R7 N C SR S

NH

NH

S

NHR7R S

NH

N

S

NHR7

O R2BrO

R2

N

S NH

H2N

O

+, X-

4 12

+i

i: DBU, DMF, 0°; then DBU and 8, r.t.

OMe

N

S

H2N

NR7

R2

O

H

-RCH2SH

8



Sequential multi-component reactions: application


N

SNC

NClH

O

Cl

Ch. Abrecht, P. Ermert, D. Obrecht; Polyphor AG, Gewerbestrasse 14, CH-4123 Allschwil

P. Maienfisch, Th. Pitterna, Syngenta Crop Protection AG, WRO-1060, CH-4002 Basel

N

SE

NR1Y

Me ClN

SE

NR1Y

ClO

E: RCO; CN

R1: CF3, NH2, 4-Cl-C6H4-; thiophen-2-yl-

Insecticidal lead compound Library

D. Obrecht et al. Chimia 2003 , 57, 262-269




R1

NH2

NH2

,X-

+

+i

R1

NH2

NH

S

NH

N

SE

NH

R1

N

SE

NR1

ii,

H

OCl

iii, iv

N

SE

NR1

R4

OCl

vi

N

SE

NR1

H

S ClO O

N

SE

NR1 S ClO O

R4

v, iv

vi

i: DIEA, DMF; ii: DBU, DMF, ECH2X; iii: 3-Cl-C6H4COCl, DCM,pyridine, DMAP; iv: TFA, DCM, H2O; v: 3-Cl-C6H4SO2Cl, DCM,pyridine, DMAP; vi: K2CO3, DMF, MeI or ClCH2OEt

E: R3CO; CN

E-CH2-X

R4: Me, CH2OEt

OMe

MeO

N=C=S

OMe

OMe

OMe

OMe




R1

NH2

NH2

,X-

+

+i

R1

NH2

NH

S

NH

N

SE

NHR1

ii,

iviii

i: DIEA, DMF; ii: DBU, DMF, ECH2X; iii: K2CO3, DMF, MeI; iv: K2CO3, DMF, ClCH2OEt

E: R3CO; CN

E-CH2-X

N=C=SCl Cl

Cl

N

SE

NR1 ClN

SE

NR1 ClMe

O




i

R'S

NH2

NH2

,X-

+

+ R2N=C=SR'S

NH2

NH

S

NHR2

N

SE

NHR2H2N

N

SE

NH2N

ii,

H

OCl

iii

N

SE

NH2NR4

O

Cl

v

i: DIEA, DMF; ii: DBU, DMF; iii: 3-Cl-C6H4COCl, CH2Cl2, pyridine,DMAP; iv: TFA, CH2Cl2, H2O; v: K2CO3; DMF CH3I or ClCH2OEt

N

SE

NH2N

Cl

R4

N

SE

NH2N

OCl

OMeMeO

iv

v

E-CH2-X

E: R3CO; CN

E: R3CO; CN

R4: Me; CH2OEt


Fragment-based screening


A. Identification of fragments:

Weak binders mM to 30M areidentified (e.g. F1-3)

B: Fragment evolution:

-An initial fragment is optimized(e.g. F1 to F1‘ and F2 to F2‘)

C. Fragment linking:

-Two ore more fragments,which bind to proximalparts of the active site, arejoined together

-very challenging

F1

F3

enzyme binding pocket

F1'

F2'

F3F1'

F2'

F3

F2

-D. C. Rees et al. Nature Rev. Drug Disc. 2004, 3, 660-672-P. Hayduk et al. Nat. Rev. Drug Disc. 2007, 6, 211-219


Dynamic Combinatorial Synthesis


COOH

NHAcH2N NH2

+R1 R2

O

COOH

NHAcN NH2

R1 R2

neuraminidase

H2O, pH 6

COOH

NHAcN NH2

R1 R2

NaCNBH3

COOH

NHAcHN NH2

R1 R2

"amplifications"

COOH

NHAcHN NH2

HO

amplification= 84Ki = 700nM

COOH

NHAcHN NH2

amplification> 30Ki = 85nM (strongest binder)

M. Hochgürtel et al. J. Med. Chem. 2003, 46, 356-8


Dynamic Combinatorial Synthesis: Disulfide Thethering


SH

IL-2

+

R1

SSR2

disulfideexchange

S

IL-2

SR binding stabilizes

disulfide S

IL-2

SR

best R series: SS O

N

AB

C

A, B, C: H, CO2H, CO2Me or MeO

improve design of a known inhibitor with tethering "hit"

NN

Me

R

ClCl

O

AB

C

NN

Me

R

ClCl

existing inhibitorIC50 = 3 M

improved inhibitorsIC50 = 0.2 M

J. A. Wells et al. Proc. Natl. Acad. Sci. USA 2000, 97, 9367-72; A. C. Brainsted et al. J. Am. Chem. Soc. 2003, 125, 3714-15


Click Chemistry


Click Chemistry: Diverse chemical function from a few good reactions

H. C. Kolb, K. B. Sharpless, Angew. Chem. Int. Ed. 2001, 40, 2004

Development of a set of powerful reactions for the rapid synthesis ofuseful new compounds and combinatorial libraries through heteroatomlinks (C-X-C); an approach called Click Chemistry.

Reactions that have a high thermodynamic driving force, usually greaterthan 20 kcal/mol

-Cycloadditions ([1,3]-dipolar additions; Diels-Alder reactions)-Nucleophilic Substitution reactions on strained heterocyclicelectrophiles

-Carbonyl Chemistry of the non-Aldol-type: synthesis of ureas, thioureas,aromatic heterocycles, oxime ethers

-Addition reactions to C-C carbon multiple bonds: epoxidations, aziridinations,dihydroxylations


Click Chemistry


Nature

Petroleum

X X: O, NR

n

R1

O

R2

N

NN

N

R1 O

R4

H

R3

NNN

R2

R1

R1-N=N=N-+

R1 R2

NXR3

R3XNH2

H. C. Kolb, K. B. Sharpless, Drug Discovery Today 2003, 8, 1128-37

XHNuc

:Nuc


Click Chemistry


NNN

Ph OH

N

HO

NN

Ph

OH

HO

NN

N N-+N-N+

Cu (turnings)(ca 1g)

H2O/tBuO(2:1)(50ml)

RT, 24hCuSO4(cat.)

(10Mol%)

+

Ph

(20.0mMol)

(10.0mMol)

3.7g (95%)white solid

V. V. Rostovtsev et al. Angew. Chem. Int. Ed. 2002, 41, 2596

[1,3]-Dipolar additions of acetylenes and azides


Click Chemistry in Drug Discovery


OO

OO

O

OO O N

OHHO

N

N

N

O

NH2

H

- -

+

RNH

ON=N=N-

+

n

NO

O

OO

O

OO O N

OHHO

N

N

N

O

NH2

H

- -

NNON

R

NO

O

OO

O

OO O N

OHHO

N

N

N

O

NH2

HNNO

N

nH

H4

Cu (turnings)(ca 1g)

H2O/tBuO(2:1)(50ml)

RT, 24hCuSO4(cat.)

(10Mol%)

Lee et al. J. Am. Chem. Soc. 2003, 125, 9588-89

Ki: 62nM; inhibition of fucosyl transferase

cancer metastasis; lymphocyte trafficking- -

Dramatic rate acceleration of the azide-alkyne cycloaddition by sequestering the two components insidethe host structure (enzyme or receptor)




-Emerging resistance in clinical isolates of bacteria render existing antibiotics suchas Neomycin and Ciprofloxaxin inactive

-Enzymes such as aminoglycoside 3‘-phsphotransferases inactivate 3‘ position inaminoglycoside antibiotics by phosphorylation

-Combination of two antibiotics has emerged as a valuable strategy to overcomerapid resistance mechanisms




N

OHOOC F

NN

XN3

O

NH2

HOHO H2N

H2NNH2

OHO

OH

HO

O

H2NO

H2N OH

Y+

N

OHOOC F

NN

X

O

NH2

HOHO H2N

H2NNH2

OHO

OH

HO

O

H2NO

H2N OH

YN

NN

Cipro-NeoB hybrids

[(CH3CN)4Cu]PF6; 7% NEt3 inH2O; microwave irridiation 40s

(yields: 30-80%)

-biological activities (MICs) dependedsignificantly on the variable spacergroups X and Y

-best combinations were X= -(CH2)2-and Y= -CH2OCH2-

-MIC (minimal inhibitory concentration):E.coli (R477-100): 3g/mlE.coli (ATCC 25922): 3g/mlE.coli (AG100A): 0.38g/mlB. subtilis (ATCC 6633): 0.75g/ml




OMe

SN

OO

OHN3

Azide 1 O

COOMe

O

O

NH OH

NH

O

OMe

NN

OMe

O

O

NH

COOMe

OH

Alkynes

x

HIV-protease (SF-2), buffer, 23°, 24h

OMe

SN

OO

OHNN N

OO

HN

HO

Ki = 1.7 nM

M. Whiting et al. Angew. Chem. Int. Ed. 2006, 45, 1435-39; K. B. Sharpless, R. Manetsch, Exp. Opin.Drug. Disc. 2006, 1(6), 525-38




Summary of fragment-based approaches:

-fragment libraries are smaller: few hundreds to thousands

-screening effort smaller; however, weak binders have to be detectable

-leads derived from fragments are often smaller; allows more extensiveoptimization

-fragments can be assembled in a thermodynamically or kinetically controlledfashion: dynamic combinatorial synthesis

-fragments can be assembled using click chemistry

-finding the appropriate linkers to assemble fragments is a big challenge


Reactions used for the introduction of high variation substituents


BB

O

OH

Formation dàmides et dùrées:

BB

O

NH(R)RHV

Amination réductrice:

BB

O

H BB NH(R)RHV

BB

Couplage Suzuki:

BBArX

Réduction au diborane:

BB

O

NH

BB NHRHVRHV

Alkylation du groupe thiol:

R1-SH + BrO

R2

R1SO

R2base

BBNH2 BB

HN

HN

ORHV


Reactions used for the introduction of high variation substituents

Chemical Biology: Combinatorial Chemistry-Parallel Synthesis2.5. Parallel reactions

Substitution nucleophillique:

N

N X

N

N NH(R)RHVBB BB

Alkylation de NH activés:

NH

O

R1

R2

N O

R1

R2

RHV

Réaction de Mitsunobu:

R1 OH

R2

R1 O

R2 O

R3

R1 OH

R2

R1 N

R2

O

O

R1 OH

R2

R1 N3

R2

R1 NH2

R2

R1 OH

R2

R1 O

R2 R3

Réaction de Mannich:

R2CHO

NH

R3

NH

R3

NR2

N NHR1

N R1


Questions


1. Please name five efficient reactions that can be used forfinal parallel derivatization?

2. Please name potential advantages of fragment-based leaddiscovery over screening large combinatorial libaries?

3. What is the rule of 3?


Examples: various parallel extraction procedures


Extractions : principle

Liquid-liquid extractions

Solid-phase extractions

Solid-supported scavengers

Ion-exchange resins

Fluorous phase extractions


Parallel work-up procedures: principle


1. Two phase extractions: manuel extraction

Upper phase: contains product (EtOAc or fluorous phase): separated manually

Lower phase: contains impurities (aqueous phase)

2. Two phase extractions: robotic system (style Tecan)

Upper phase: contains impurities (aqueous phase): separated by robot

Lower phase: contains product (CHCl3 or CH2Cl2): dried and evaporated


Parallel work-up strategies: liquid-liquid extractions


1. Two phase extractions: solubilize impurities in the aqueous phase

Me2N(CH)nNH2

H2N

S

NHR1 + BrO

R3

R2

1 2

N S

R1HN

R3R2

3

1. MeOH, 60°

2. 4, 60°

3. aq.NaOHCH2Cl2

HOOC

HN

S

NH2 excess 2

HOOC

HN

N

S

R2

R3

4 5

Products of type 5 are soluble in the basic aqueous phase

A. Chuchulowski, T. Masquelin, D. Obrecht, J. Stadlwieser, J.-M. Villalgordo, Chimia 1996, 50, 530


Parallel work-up strategies: solid-phase extractions


Solid phase extractions/filtrations

Solid phase: one or several solid pahses are filled into a polypropylene syringe orcartridge

Solid phases: SiO2; Al2O3; `ìon exchange resins (basic, acidic and mixed bed)``;Kieselguhr; MgSO4; polymère functionalisé: -NH2, -SH, -PPh2, COOH, CHO,CH2OH, isothiourée, N3...;

The organic phases are passed through these cartridges in order to get rid ofimpurities which are adsorbed onto the solid phase. They can be appliedmanually or by a robotic system (Tecan)


Parallel work-up strategies: solid-supported scavengers


R1-NH2

R1-NHCONHR2R2-N=C=O

R3-COCl

R4-SO2Cl

R1-NHCOR3

R1-NHSO2R41

2

3

4

NH2 NHCONHR2

NHCOR3

NHSO2R4

excess


Parallel work-up strategies: solid-supported scavengers


Parallel synthesis in solution using polymer-bound reagents

GPNH

R'O

RP2

P1

P1'

cysteine trap

CbzHN COOH

R

NO

O

O

Cl

DMF, -5°

1)

2) CH2N2/DCM

-10°, 1h

CbzHN

R

ON2

NH

+

Br-

DMF, 1.5h, 25°

CbzHN

R

OBr

N

R1R2NHorR3SHDCM, 18h

CbzHN

R

ONR1R2

or

CbzHN

R

OSR3

CbzHNO

NH

HN

PhCbzHN

OS

HN

S

N

N. Y. Yadav-Bhatnagar, N. Desjonquères, J. Mauger, J. Comb. Chem. 2002, 4, 49-55

85-90%(5-10% methylester)

80-85%

i

i


Parallel work-up strategies: solid-supported scavengers; intermediate catch


Parallel synthesis in solution using polymer-bound reagents

("intermediate catch" or "resin capture"COOH

N3

R3

+

R1NH2

+

O

CHOR2

+

R4N=C

DCM, 0°

PPh3

NO R1

O

NHR5

O

R3

R2

NNN-

+

NO R1

O

NHR5

O

R3

R2

NP

Ph Ph

toluene, 60°

wash

N

N

OR1

O

NHR5R3

R2

A. Chucholowski, D. Heinrich, B. Mathis, C. Müller, Generation of benzodiazepin and benzodiazocin libraries through resin captureof Ugi-4CC, conference: 214th ACS national meeting, Las Vegas, 1997


Parallel work-up strategies: fluorous phases


Substrate

FP

+

FP: fluorous phase; C6F13CH2CH2- or C10F21CH2CH2-

Substrate

FPliquid phase reactions

Products

FP+ excess reagents

liquid-liquid extraction

Products

FP1. cleavageProducts

2. extraction




(Rf)3Si

COOH

Rf: C10F21CH2CH2-

+

R1NH2

R2CHO

R3N=C

i, ii

(Rf)3Si

O

NR1

R2

NHR3

O

Multicomponent reactions: fluorous phase extraction

O

NR1

R2

NHR3

O

iii, ii

i: TFE, 90°, 48h; ii: liquid-liquid extraction; iii: Bu4NF, THF, rt

A. Studer, S. Hadida, R. Ferritto, S.-Y. Kim, P. Jeger, P. Wipf, D. Curran, Science 1997, 275, 823




(Rf)3Si

Rf: C6F13CH2CH2-

O

O

NN

(Rf)3Si

O

O

NN Me+

i

OTf-(Rf)3Si

O

O

NH COOH

X

(Rf)3Si

O

O

NH

X

NHO

O

1 2 3

4

ii

iii

NH

N

O

O

O

X

Fluorous phase extraction: cleavage by cyclization

iv

i: MeOTf, CH2Cl2, 1,1,1-(trifluoromethyl)benzene(BTF); ii: anthranilic acid, DMAP, BTF, CH2Cl2; iii: TBTU, furfuryl amine, THF;iv: Et3N

D. Schwinn, W. Bannwarth, Helv. Chim. Acta 2002, 85, 255


What are the prime biological targets?

Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis6. Case studies

-Kinases: 22%; market: 2 drugs-GPCR: 15%; ¨ : 30%-Ion channels: 5%; ¨ : 7%-Ser proteases: 4%; ¨ : 1 drug-Phosphatases: 4%;-Zn proteases: 2%; ¨ : ACE inhibitors-Nuclear receptors: 2%; ¨ : 4%-others* : 44%;

*Many targets involving large surface protein-protein interactions

-despite the fact that kinases, CPCR‘s and ion channels constitute only about 42% ofall targets of therapeutic interest, the pharmaceutical industry is devoting about 90% oftheir resources to those targets; it is believed that these targets can be adressed withsmall molecules.-The number of biologicals (antibodies, fusion proteins, peptides) reaching the marketis increasing. These molecules target mainly large surface protein-protein interactions


Targets hit by current drugs


Drugs, their targets and the nature and number of drug targets

P. Imming et al. Nature Rev. Drug Disc. 2006, 5, 821-34

1. Number of drug targets :

1997 : Drews et al. Nature Biotechnol. 1997, 15, 1318-19

-Marketed drugs hit 482 targets ; human genome suggests 100'000 proteins

2002: J. Burgess et al.

-after sequencing of human genome: ~8000 targets~5000 hit by known drugs: 2400 byantibodies; 800 by proteins

2002: A. Hopkins et al. Nature Rev. Drug Disc. 2002, 1, 727

-on the basis of ligand binding studies: 399 targets, which belong to 130 target families~3000 targets amenable to small molecules

bottom line: 300-500 targets hit by current drugs; 3’000-8’000 drugable targets



Kinase inhibitors


-Recent reviews: A. J. Bridges, Chem. Rev. 2001, 101, 2541-2571; G. Scapin, Drug Disc.Today 2002, 77,601-611; S. Orchard, Curr. Opin. Drug Disc. & Dev. 2002, 5, 713-717; D. Fabbro, C. Garcia-Echeverria,Curr. Opin. Drug Disc. & Dev. 2002, 5, 701-712; S. K. Hanks, The FASEB J. 1995, 9, 576-596 (sequences ofkinases); M. E. M. Noble, J. A. Endicott, L. N. Johnson Science 2004, 303, 1800-5; J. Zhang; P. L. Yang; N.S. Gray, Nat. Rev. Drug Discov. 2009, 9, 28-39 (Targeting cancer with small molecule kinase inhibitors);

-Three families of kinases: -Serine-threonine kinases (S/TKs)

-Tyrosine kinases (TKs)

-Dual function kinases (DFKs)

-Roughly 2000 kinases known in the human genome

-Kinases phosphorylate serine, threonine and tyrosine and are ATP dependent

OH

TKs)

ATP

OPO

O-

O-

OHR *TKs)

ATP

OR * PO-

OO-

phospatases phospatases


Kinase inhibitors: 3D-structure of kinase domain


DDT 2002,77, 601-611



Nat. Rev. Drug Discov.2009, 9, 28-39











Kinase inhibitors on the market



CPCR’s: introduction


50% of all drugs target G-Protein-Coupled Receptors (sales in 2001: ~50billion USD)

G-protein: guanin nucleotide-binding protein

-240 receptors with known ligands from which only ~30 are currently investigated by pharmacompanies

-An additional 160 receptors with unknown ligands (orphan receptors) are known

Family 1: rhodopsin-like or adrenergic-like GPCR‘s

constitute the largest family; contain a short N-terminus and amino acid residuesin the trans-membrane domain are highly conserved

Family 2: glucagon receptor-like or secretin receptor-like GPCR‘s

Family 3: metabotropic glutamate receptors

Drug design strategies for targeting G-protein-coupled-receptors: Th. Klabunde, G. Hessler,ChemBioChem 2002,3, 928-44.

3D-structure of bovine rhodopsin: Science, 2000, 289, 739-45; Biochemistry, 2001, 40, 7761-72.


CPCR’s: introduction


Extracellular

Cytoplasmic

COOH-

-NH2

i1

i2

i3

e1e2 e3

TM1 TM2 TM3 TM4 TM5 TM6 TM7

GG--proteinprotein--coupled receptorscoupled receptors

-S-S-


GPCR’s: some best-selling drugs


N Cl

N

O OEt

Claritin (Schering-Plough, H1 antagonistallergies, 3.1billion USD, 2001)

S

N

HN

N

N

H2N COOH

Neurontin (Pfizer, GABA B-agonistneurogenic pain, 2.35 billion USD, 2001)

Zyprexa (Ely Lilly, D2/D1/5-HT2allergies, 2.35 billion USD, 2001)

HO

HO

OHNH

O

Serevent (Glaxo, 1 agonistasthma, 0.91 billion USD, 2001)

N COOHN

NNHN

Diovan (Novartis, AT1 antaginisthypertension, 0.8 billion USD, 2001)



NMDA: Brain ischimia, CNS-trauma, epilepsy, huntingtondisease2.3 million patients

NMDAAMPA

KAINATE

Extracellular ligandgated channels

Na: Migraine, back pain,34 mio. patients USCa: Hypertensionpatients US, prostate cancerK: MS, spinal cord injury250000 patients US

>15 subtypes35 subtypes> 100

subtypes50% not yetcharactarized

Na+

Ca ++

K+

Voltage gatedchannels

Not considered here

14 subtypes

CAMPcGMPCA ++

G-proteins

Intracellular ligandgated channels

AChR: Neuromuscular Disorder300000 patients US

Migraine, depressionHydroxy-tryptamin type

Nicotinoid AChRGABAGlycine5-HT3

Extracelluular ligandgated channels


Case study 1: Inhibitors of influenza endonuclease


BocHN

F

NO2 BocHN NO

OPivR1

OPiv

RHN NO

OHR1

OH

Inhibitors of influenza endonuclease: collaboration between Roche and Polyphor Ltd




- Influenza infects an estimated 120 Mio. people in US, Europe and Japan in a typical year

-The influenza endonuclease is an attractive target for several reasons:

i: It is a key component of the viral transcription mechanism, which has no cellular counterparts andshould therefore provide a good potential for discovering selective, non-toxic drugs

ii: In contrast the neuraminidase inhibitors that do not prevent the formation of new virus particles, but interferewith virus release from host cells and are therefore virustatic, endonuclease inhibitiors, due to the block of viraltranscription, are expected to have a virucidal effect.

Disease and target




Ketobutanoates N-Hydroxy-imides

O OH

O

OH

O OH

O

OMe

Merck: IC50: 21.3M

Merck: IC50: >500M

O OH

O

OH

Roche: IC50 5M

O OH

O

OH

Roche: IC50: 0.43M

NPh

Cl

N

N

O OOH

Merck : IC50: 5.5M

Flutimide: fungal methabolite

N

N

O OOH

Merck: IC50: 0.9M

F

N

O

OOH

Roche: IC50 15M

N

N

N

HN O

O

OH

Roche: IC50 95M

N

O

O

OH

Roche: IC50 >1000M

HN

OHO

Roche: IC50 >500M N

O

ONH2

Roche: IC50 800M




Ketobutanoates N-Hydroxy-imides

O OH

O

OH

Merck: IC50: 21.3MN

N

O OOH

Merck: IC50: 5.5M

Flutimide: fungal methabolite

NO

OH

R2

OHR1

NOH

OH

R2

OR1

N-Hydroxy-tetramic acids




NO

OH

R2

OHR1

NOH

OH

R2

OR1

N-Hydroxy-2-indolinones

N

OH

O

OHRHN

R1

1




N

OH

O

OHRHN

R1

-N-hydroxy-2-indolinone derivatives 1 were not described in the literature

1

hydroxamic acid moiety

-keto amide moiety

high variation site

-Molecules of type 1 bear two potentially reactive and labile functional groupsfor which suitable protective groups have to be found

-Molecules of type 1 are acidic and polar and thus problems of isolation and purificationwere anticipated; especially for a parallel approach




N

OCOR2

O

OPGH2N

R1

2

N

OH

O

OHNH

R1

O

R3

N

OH

O

OHNH

R1

O

R4HN

1A

1B

N

OH

O

OHNH

R1

SR5

1C

key precursors for parallel synthesis

N

OH

O

OHRHN

R1

1

O O

PG: protective group




NO

OPivBocHN BocHN NO2

3 4

COOH

N

OCOR2

O

OPGH2N

R1

2

key precursors for parallel synthesis




H2N

F

NO2 BocHN

F

NO2 BocHN NO2

CH(COOMe)2

6 7 5

i ii

i: Boc2O, THF, 80°; ii: CH2(COOMe)2, NaH, DMSO; iii: aq. NaOH, MeOH, reflux




NO

OCOtBuBocHNBocHN NO2

4 3

iv, v

iv: Pt/C(5%),H2, DMSO, EtOH; then AcOH; v: tBuCOCl, DIPEA, CH2Cl2

COOH

problemes:

-partial reduction of nitro group-cyclization-isolation of hydroxamic acid




NO

OPivBocHN

3

N

O

O

OPivBocHN

R1

i: 9a: X=OCOCH3; 9b: X=Cl; 9c: X=Cl, DMAP, DIPEA, CH2Cl2, THF; 0°-r.t.; ii: tBuCOCl,tetrabutylammonium cyanide or NaCN, pyridine, CH2Cl2

R1O

ii

N

O

O

OPivBocHN

R1O

9a (R1= Me)

9b (R1= Et)

9c (R1= Ph)

R1COX(2.5 equiv.)

i

10a (R1= Me)

10b (R1= Et)




N

O

O

OPivBocHN

MeO

10a

N

O

O

OPivBocHN

O

10b

N

O

O

OPivBocHN

PhO

9c

N

O

O

OPivH2N

MeO

2a

N

O

O

OPivH2N

O

2b

N

O

O

OPivH2N

PhO

2c

i

i

i

i: 4N HCl/dioxane or CF3COOH/CH2Cl2 ; then extraction with aq. sat. NaHCO3 solution and CH2Cl2




i: R3COCl, pyridine (DIEA), DMAP, CH2Cl2; ii: R4N=C=O, CHCl3 (ethanol-free), 70°; iii: R5SO2OCl, pyridine (DIEA), DMAP, CH2Cl2

N

OCOR2

O

OPiv

R1

O

R3 NH

N

OCOR2

O

OPiv

R1

O

R4HN NH

N

OCOR2

O

OPiv

SR5 N

H

R1

O O

i

ii

iii

11a

11b

11c

N

OCOR2

O

OPiv

R1

H2N

2a (R1= Me; R2= tBu)

2b (R1= Et; R2= tBu)

2c (R1= R2= Ph)




N

OH

O

OH

Me

O

NH

N

OH

O

OH

Ph

O

NH

NH

- out of the library of 131 compounds 26 had an IC50< 50M

HOOC

IC50= 3M; EC50= 6M

IC50= 9M; EC50= 21M

N

OH

O

OH

Ph

SNH

IC50= 48M

SO O

compounds are antiviral in cell cultures




-Based on a pharmacophor hypothesis, novel 1-hydroxy-indolin-2-ones were proposedas inhibitors of influenza endonuclease

-A parallel synthesis was developed which allowed to synthesize a library 131 compoundsin significant quantities (6-71 mg) and high purities (75 - 99%) within 4 months

-From 131 compounds tested 26 had an IC50< 50M

-From 26 active compounds 10 showed a good antiviral activity in cell cultures


Case study 2: Structure-based DesignInhibitors of Metalloproteinases: TACE; MMP1


-Ligand-based design capitalizes on the presence of existing structural similarities betweena set of compounds and the active ligand (also pharmacophore-based drug design)

-Using a solid-phase, parallel synthesis approach optimization could be achieved efficiently-TNF-converting enzyme (TACE) represents an attractive target for reducing circulating levelsof the proinflammatory protein tumor necrosis factor alpha (TNF-).

-TACE belongs to the Zn-metalloproteinases. The hydroxamic acid moiety chelates to the Zn-atom located in the active site


Case study 2: Structure-based DesignInhibitors of Metalloproteinases: TACE; MMP1


M. Abou-Gharbia, J. Med. Chem. 2009, 52, 2-9


Case study 3: Parallel synthesis of analogues of antibiotic GE2270 A


N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

MeO

N

O

N

O

CONH2

GE2270 A

active against many gram positive pathogensMIC 0.06-1.0 g/ml; low solubility in aqueous solvents

N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

MeO

O

OH

1

Parallel synthesis starting from a natural product-derived building block

J. W. Jacobs et al. (Versicor), 40th annual ICAAC conference, Toronto, Canada, september 17-20th, 2000, Poster 2193 and 2194

inhibitor of elongation factor EF-TU






N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

MeO

O

OH

R

NS

O

OF

FF

F

F

R

NS

OO

O

NO2

1

2

3

R

NS

OO

O

NO2

4

R

NS

NH

OO

NO2

5






R

NS

O

OF

FF

F

F

R

NS

OO

O

NO2

2

3

R

NS

N

OR2

R

NS

ON

O

6

7

R1

R1R2NH

R1: COOHOH

Solubility(mg/ml)

0.5

GE2270 A <0.0001

R1: COOH 0.5

R2

R2=H

R1:

R2=Me

COOH 0.73

R1R1R2NH R2=H

R1:

R2=Me

COOH 0.91






N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

HO

N

O

N

O

CONH2

GE2270 D2

N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

HO

O

OH

8






N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

HO

O

OH

8

N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

HO

O

O

9

FF

F

FF

DCC, Pfp






N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

HO

O

O

9

FF

F

FF

N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

R2S

O

NHR1

10

i:R1NH2, DMF, DIEA; ii: H2O; then precipitation + wash; iii: Ts2O; CH2Cl2; DIEA; iv: R2SH, DMF/aq. K2CO3; then precipitation + wash;v: TFA/CH2Cl2 (1:1); Et2O; then precipitation + wash; then dry

R1: COOH

Solubility(mg/ml)

0.44

GE2270 A <0.0001

R1: COOH >2.0

R2=

R2= SCH3

R1:

R2= SCH3

COOH 0.41

NCOOH






N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

S

O

HN

12

Solubility(mg/ml)

GE2270 A <0.0001

>2.0

N

COOH

12

N

S

N

NS

N

S

OHHN O

NH

O

N S

O

N

S

HN

S

N NH

MeHNO

O

MeO

N

O

N

O

CONH2

GE2270 A

MIC(MRSA)(g/ml)

0.125

0.5

COOH


Case study 4: Parallel synthesis based on Natural Products



-Rapamycin is a immunosuppressant natural product, which has two binding sites. It bindsto the FKBP domain and to mTOR (kinase) effector domain. Besides its immunosuppressantactivity the synthetic analogue torisel shows potent anti-tumor activity and is used for treatmentof renal carcinoma. Torisel was obtained through a parallel synthesis approach from rapamycin.





-Using a parallel synthesis approach starting from the natural product rapamycin, the alcoholgroup was derivatized with various different substituents.





-ILS-920 is a semi-synthetic rapamycin derivative which lacks the immunosuppressant activitybut shows neuroprotective properties. It shows good brain penetration.


Case study 5: kinase inhibitors


-Recent reviews: A. J. Bridges, Chem. Rev. 2001, 101, 2541-2571; G. Scapin, Drug Disc.Today 2002, 77,601-611; S. Orchard, Curr. Opin. Drug Disc. & Dev. 2002, 5, 713-717; D. Fabbro, C. Garcia-Echeverria,Curr. Opin. Drug Disc. & Dev. 2002, 5, 701-712; S. K. Hanks, The FASEB J. 1995, 9, 576-596 (sequences ofkinases)

-Three families of kinases: Serine-threonine kinases (S/TKs)Tyrosine kinases (TKs)Dual function kinases (DFKs)

involved in cell signaling pathways

-Roughly 2000 kinases known in the human genome

-Kinases phosphorylate serine, threonine and tyrosine and are ATP dependent

OH

TKs)

ATP

OPO

O-

O-

OHR *TKs)

ATP

OR * PO-

OO-

phospatases phospatases


Case study 5: kinase inhibitors


-Some important kinases: protein kinase C (PKC: 12 isoforms); PKC: involved in cellproliferation; target in cancer therapy

Growth factor receptor kinases: EGF (epidermal groth factor);TGF (transforming growth factor); PDGF (platelet-derivedgrowth factor); VEGF (vascular endothelial growth factor); TNF (tumornecrosis factor); NGF (nerve growth factor)

MAP-kinase (mitogen activated kinase); CDKs (cyclin-dependentkinases); JAK’s (Janus family of TKs); Abl (Abelson TK); targets incancer and inflammation; and many more

N N

HN

OMe

O

NHMeOMe

Staurosoporine (IC50(PKC): 2.5nM)(non-specific to other PKC-isoforms)

O O

O

COOMe

O

OH

O

O

OHOMeOOC

OH

OH

Bryostatin 1

some early naturalproduct leads

H

N

N N

N

NH

HO

NH

Ph

Olomoucine (IC50(CDK): 4.5M)


Case study 5: parallel synthesis of olomoucine analogues


N

N N

N

NH

HO

NH

Ph

Olomoucine (IC50(CDK): 4.5M)

N

N N

N

HH2N

Cl

N

N N

N

HF

Cl

N

N N

N

HF

NH

NH2

i ii, iii

N

N N

N

HF

NH

HN

MeO

MeO

OHC O

HN

OC

L

L: PAL-linker

N

N N

N

R1F

NH

HN L

N

N N

N

R1R2HN

NH

NH2

iv

v vi, vii

building block synthesis

parallel synthesis

i: 0.3M NaNO2, HBF4 (48% in H2O), -15°; ii: 4-nitro-benzylamine hydrochloride, DIEA, n-BuOH, 50°; iii: H2, Pd/C; iv: NaBH(OAc)3,1% AcOH, DMF; v: R1-OH, PPh3, DEAD, CH2Cl2/TFA (1:1); vi: R2-NH2, n-BuOH/DMSO (4:1), 90-100°, 48h; vii: TFA/H2O/Me2S (90:5:5)

P. G. Schultz et al. Tetrahedron Lett. 1997, 38, 1161


Case study 6: Orexin receptor (OX1 and OX2) antagonists


R. Koberstein et al. Chimia 2003, 57, 270-275.

-Orexin receptor 1 (OX1) and orexin receptor 2 (OX2) belong to the GPCR‘s and arebelieved to modulate appetite, food intake and sleep.

-The two endogenous neuropeptides orexin A and B bind to both OX1 and OX2:orexin A: IC50=20nM (OX1); IC50=36nM (OX2)orexin B: IC50=420nM (OX1); IC50=38nM (OX2)

-Actelion initiated a program in developing orexin antagonists as modulators of sleep

-HTS delivered a hit compound 1 which served as starting point for several follow-uplibraries of type 2.

NNH

OMeO

MeOMeO

MeO

1

NN

O

R1

R5

R6

2

R7

R4

R3

R8 R2





Library 1

NH

MeO

MeOMeO

MeO

N

MeO

MeO

MeO

MeO

N

OR1

R2

Br

OBr1)

2) DIEA; NHR1R2N

MeO

MeO

MeO

MeO

NH

O

OMe

IC50=19nM (OX1); 101nM (OX2)>100 analogues

Library 2

X

O

R3

X: Cl, OH

+MeO

MeONH2

NH

MeO

MeO

R3

N

MeO

MeO

R3

N

OR1

R2

POCl3

NaBH4





Library 2 Library 3

N

MeO

MeO NH

O

IC50=18nM (OX1); 1161nM (OX2)

N

MeO

MeO NH

O

X

Y

X=H; Y=NMe2: IC50=45nM (OX1); 1536nM(OX2)X=Y=F: IC50=1906nM (OX1); 19nM (OX2)

-Substituent R8 can modulate the selectivity towards OX1 and OX2

-OX2 specific compounds can be made


EC50: effective dose for a 50% of maximal response

Dose: in mg/kg: mg of compound per kg of body weight; e.g. 1mg in a 25g mouse is the equivalentof 2g dose in a 50kg (small) adult.

SAR: structure activity relashionship. Correlation between chemical structure and biological activity.

Phase I: In phase I clinical trials a compound is dosed to healthy volunteers and three main questionsare asked:

1. Is the compound safe at the proposed dose?2. What are the limiting side effects likely to be?3. How long does the compound stay in the system?

Phase II: Phase II clinical trials aim at showing efficacy of the compound in a sample of patients having aparticular disease. If there are signs that the compound is active enough it can be promoted tonext phase.

Phase III: Phase III clinical studies are big and comprise many patients. The key issues are the following:How well does the drug work?What are its side effects at the proposed efficacy doses?What kind of a dosing schedule is optimal?How does it interact , favorably or unfavorably, with other drugs for the same or related conditions?

Success: At least 25000 compounds have to be made in order to get one drug expenses are around500 million USD with a lead time of 7-10 years.

Some useful definitions in medicinal chemistry

Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis7. Appendix (Definitions; Reviews; Literature


Targets: Up to now only about 200 discrete molecular targets have been explored. Around 50% of thesebelong to the GPCR’s (e.g. histamine, dopamine or serotonin receptors). With decoding of thehuman genome it is believed that 30’000 targets will be unveiled.

Protein structure: -primary sequence: genomics-sequence alignment with known proteins: conserved residues are characteristic for function-gene knockout can reveal importance of a target for a certain disease-expression and purification-3D structural determination by X-ray or NMR techniques-mutagensis studies (site directed mutagenesis) can reveal important residues in receptors or ligands

Protein kinases: transfer the g phosphate of ATP to side chain hydroxyls of substrate proteins.It is estimated that about 2000 kinases exist in the human genomeSerine/threonin kinases (S/TK’s)Tyrosine kinases (TK’s)Dual function kinases (DFK’s)

Protein phosphatases: cleave phosphate groups from substrate proteins

Some useful definitions in medicinal chemistry



ADMET: Adsorption, Distribution, Metabolism, Elimination and Toxicity


ADMET: Adsorption, Distribution, Metabolism, Excretion(Elimination) and Toxicity

In vitro ADMET experiments:

-Cytotoxicity assay on different cancer cell lines

-Stability in plasma: rodents (mouse, rat), human

-Caco 2 cell passage of compounds: indicator for oral absorption

-Passage of compounds through artificial membranes (PAMPA)

-Metabolism studies in liver microsomes: first pass metabolism

-Protein binding (binding to serum albumin): indicates availability of compound in plasma




2. Target classes: -2.1. Enzymes-2.2. Substrates, metabolites and proteins-2.3. Receptors-2.4. Ion channels-2.5. Transporter proteins-2.6. DNA/RNA and the ribosome-2.7. Targets of monoclonal antibodies-2.8. various-2.9. unknown

2.1. Enzymes: -Oxidoreductases (e.g. MAO-B, aromatases etc.)-Transferases (kinases, phosphatases, DNA polymerases etc.)-Hydrolases (serine proteases, metalloproteases etc.)-Lyases (DOPA decarboxylase, carbonic anhydrase etc.)-Isomerases ((DNA gyrases, topoisomerases etc.)-Ligases (dehydropteroate synthase, mTOR etc.)




2.3. Receptors: -Direct ligand-gated ion channels (GABAA, acetylcholine R,glutamate R)-GPCR’s (class 1, class 2 (secretin-like), others)-Cytokine receptors-Integrin receptors-Receptors associated with TK-Nuclear receptors

2.4. Ion channels: -Voltage-gated Ca2+ channels (L- and K-type)-K+ channels (epithelial, voltage-gated)-Na+ channels (epithelial voltage-gated)-RIR-CaC-TRP-CC-Cl- channels

2.5. Transporter proteins: -Cation-chloride cotransporter (CCC)-Na+/H+ antiporters-Proton pumps-Eukariotic sterol transporters-Neurotransmitter/ Na+ symporter-Noradrenalin/Na+ symporter-Dopamine/Na+ symporter




2.6. DNA/RNA and the ribosome:-Nucleic acids-RNA (16S-rRNA; 23S-rRNA)-Spindle (tubulin, kinesins)-Ribosome (30S subunit; 50S subunit)

2.7. Targets of monoclonal antibodies:-Vascular endothelial factor (VEGF; e.g.bevazizumab; Avastin)

-Lymphocyte function-associated receptor(LFA-1; efalizumab)

-Epidermal growth factor receptor (EGFR)(e.g. cetuximab)

-h-EGFR-2 (e.g. trastzumab; Herceptin)-Immunoglobulin E (IgE; e.g. omalizumab;Xolair)

-CD-3-CD-20 (Rituximab; Mabthera)-CD-33 (Gemtuzumab))-CD-52 (Alemtuzumab)-TNF(Adalimumab; infliximab; Enbrel)




G-Protein Coupled Receptors (GPCR’s):-Acetylcholin receptors (muscarinic receptors;MCR 1-4)

-Adenosin receptors-Adrenoreceptors (1, 2, 1)-Angiotensin receptors-Calcium-sensing receptors-Cannabinoid receptors (CB1, CB2)-Cysteinyl-leukotriene receptors-Dopamine receptors-Endothelin receptors-GABAB recptors-Glucagon receptors-Glucagon-like peptide-1 receptor (GLP-1R)-Histamin receptors (H1, H2)-Opioid receptors (, , )-Neurokinin receptors (NK1, NK2, NK3)-Prostanoid receptors-Prostamide receptors-Purinergic receptors-Serotonin receptors (5-HT1A, 5-HT1B/1C,5-HT2a, 5-HT3, 5-HT4)

-Vasopressin receptors (V1, V2, OT)




Cytokine receptors: -Growth hormone receptor-Erythropoetin receptor (EPO)-Granulocyte colony stimulating factor receptor (G-Interleukin-1 receptor (IL-1R)-Interleukin-2 receptor (IL-2R)-Tumour necrosis factor (TNF)

Integrin receptors: -Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)

Receptors associated with TK: -Insulin receptor

Nuclear receptors: -Mineralcorticoid receptor-Glucocorticoid receptor-Progesteron receptor-Oestrogen receptor-Androgen receptor-Vitamin D receptor-ACTH receptor-Retinoic acid receptor (RXR)-Peroxisome-proliferator-activated receptors (PPAR; -Thyroid hormone receptor


4. Appendix-Reviews

Medicinal Chemistry : Combinatorial Chemistry-Parallel Synthesis7. Appendix (Definitions; Reviews; Literature)

-Applications of Combinatorial Technologies to Drug DIscovery. 1. Background and Peptide Combinatorial Libraries.M. A. Gallop, R. W. Barrett, W. J. Dower, S. P. A. Fodor, E. M. Gordon, J. Med Chem. 1994, 37, 1233

-Applications of Combinatorial Technologies to Drug DIscovery. 2. Combinatorial Organic Synthesis, Library ScreeningStrategies, and Future Directions. M. A. Gallop, R. W. Barrett, W. J. Dower, S. P. A. Fodor, E. M. Gordon,J. Med Chem. 1994, 37, 1385

-Combinatorial Libraries. Synthesis, Screening and Application Potential. R. Cortese (Ed.), W. De Gruyter, Berlin (1995)

-Combinatorial Peptide and Nonpeptide Libraries. G. Jung (Ed.), VCH, Weinheim (1996)

-Kombinatorische Synthese. K. Frobel, T. Krämer, Chemie in unserer Zeit 1996, 30, 270

-Organic synthesis on solid phase. J. S. Früchtel, G. Jung, Angew. Chem. Int. Ed. Engl. 1996, 35, 17

-Combinatorial synthesis of small-molecular-weight organic compounds. F. Balkenhohl, C. Bussche-Hünnefeld,A. Lansky, C. Zechel, Angew. Chem. 1996, 108, 2436

-Solid-phase organic reactions: a review of recent literature: P. H. H. Hermkens, H. C. J. Ottenhejm, D. Rees,Tetrahedron 1996, 52, 4527


4. Appendix-Reviews


-Synthesis and application of small molecule libraries: L. A. Thompson, J. A: Ellman, Chem. Rev. 1996, 29, 132

-Strategy and tactics in combinatorial organic synthesis. Applications to drug discovery. E. M. Goron, M. A. Gallop,D. V. Patel, Acc. Chem. Rev. 1996, 29, 144

-Design, synthesis and evaluation of small-molecule libraries. J. A. Ellman, Acc. Chem. Res. 1996, 29, 132

-Multiple-component condensation startegies for combinatorial library synthesis: R. W. Armstrong, A. P. Combs,S. D. Brown, T. A. Keating, Acc. Chem. Res. 1996, 29, 123

-Combinatorial organic synthesis using Parke-Davies‘s DIVERSOMER method: S. Hobbs-DeWitt, A. W. Czarnik,Acc. Chem. Res. 1996, 29, 114

-Combinatorial Chemistry, Synthesis and Application. S. Wilson, A. W. Czarnik, Wiley 1997

-The current status of heterocyclic combinatorial libraries: A. Nefzi, J. M. Ostresh, R. A. Houghthen, Chem. Rev.1997, 97, 449

-Organic synthesis on soluble polymer supports: Liquid phase methodologies: D. J. Gravert, K. D. Janda, Chem. Rev.1997, 53, 5643


4. Appendix-Reviews


-Synthesis and application of small molecule libraries: L. A. Thompson, J. A: Ellman, Chem. Rev. 1996, 29, 132

-Recent developments in soliud-phase organic synthesis: R. Brown, Contemporary Organic Synthesis 1997, 4, 216

-Solid-PhaseOrganic Reactions II. A Review of the Recent Literature. P. H. H. Hermkens, H. C. J. Ottenheijm,D. C. Rees, Tetrahedron 1997, 53, 5643

-Functionalized polymers: Recent developments and new applications in synthetic organic chemistry: S. J. Shuttleworth,S. M. Allin, P. K. Sharma, Synthesis 1997, 1217.

-Functionalized resins and linkers for solid-phase synthesis of small molecules: C. Blackburn, F. Albericio, S. A. Kates,Drugs of the Future 1997, 22, 1007

-Solid supported combinatorial and parallel synthesis of small-molecular-weight compound libraries: D. Obrecht, J. -M.Villalgordo, Tetrahedron Organic Chemistry Series, Vol 17, Pergamon, 1998.

Very recent reviews:

-Combinatorial carbohydrate chemistry: L. A. Marcaurelle, P. H. Seeburger, Curr. Opinion Chem. Biol. 2002, 6, 289-296

-Combinatorial synthesis of natural products: J. Nielsen, Curr. Opinion Chem. Biol. 2002, 6, 297-305


4. Appendix-Reviews


-Combinatorial synthesis of natural products: J. Nielsen, Curr. Opinion Chem. Biol. 2002, 6, 297-305

-Recent advances in isocyanide-based multicomponent chemsitry: A. Dömling, Curr. Opinion Chem. Biol. 2002, 6,306-313

-High speed combinatorial synthesis utilizing microwave irridiation: C. O. Kappe, Curr. Opinion Chem. Biol. 2002, 6,314-320

-Applications of parallel synthesis to lead optimization: M. Altorfer, Ph. Ermert, J. Fässler, S. Farooq, E. Hillesheim,A. Jeanguenat, K. Klumpp, P. Maienfisch, J. A. Martin, J. H. Merrett, K. E. B. Parkes, J. –P. Obrecht, Th. Pitterna,D. Obrecht, Chimia 2003, 57, 262-269

-Versatile monitoring tools in parallel solid-phase synthesis: E. R. Felder, K. Martina, S. Scarpella, M. Tato, Chimia2003, 57, 229-236.

-The analytical challenge: Keeping pace with combinatorial chemistry: D. B. Kassel, P. L. Myers, Pharmaceutical News2002, 9, 171-177.

-Synthetic aspects of combinatorial chemistry: P. Wipf, Pharmaceutical News 2002, 9, 157-169.

-Multicomponent reactions: emerging chemistry in drug discovery from xylocain to crixivan: Ch. Hulme, V. Gore,Curr. Med. Chem. 2003, 10, 51-80


4. Appendix-Reviews


-Drug design strategies for targeting G-protein-coupled-receptors: Th. Klabunde, G. Hessler, ChemBioChem 2002,3, 928-44.

-Protein kinase inhibitors from the urea class: J. Dumas, Curr. Opin. Drug Disc. 2002, 5, 718-27.

-Inhibitors of the JNK signaling pathway: S. J. Harper, P. LoGrasso, Drugs of the Future 2001, 26, 957-73.

-Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer therapy-clinical progress:P. A. Renhowe, Curr. Opin. Drug Disc. 2002, 5, 214-224.

-Kinases as targets: prospects for chronic therapies: S. Orchard, Curr. Opin. Drug Disc. 2002, 5, 713-727.

-Current progress on farnesyl protein transferase inhibitors: S. B. Singh, R. B. Lingham, Curr. Opin. Drug Disc. 2002,5, 225-44.

-Medicinal chemistry of target family-directed masterkeys: G. Müller, Drug Disc. Today 2003, 8, 681-91.

-Topics in drug design and discovery: Chapter 26. Privileged structures-an update: A. A. Patchett, R. P. Nargund,Ann. Rep. Med. Chem. 2000, by Academic Press.

-Drugs, leads and drug-likeness: an analysis of some recently launched drugs: J. R. Proudfoot, Bioorg. Med. Chem.Lett. 2002, 12, 1647-50.


4. Appendix-Reviews


-Protein kinase inhibitors: insights into drug design from structure: M. M. Noble, J. A. Endicott, L. N. Johnson,Science, 2004, 303, 1800-5.

-Small-molecule inhibitors of protein-protein interactions: progressing towards the dream: M. R. Arkin, J. A. Wells,Nature Reviews Drug Discovery 2004, 3, 301-17.

-NMR in drug discovery: M. Pellecchia, D. S. Sem, K. Wüthrich, Nature Reviews Drug Discovery 2002, 1, 211-19.

-Chemical inhibitors of Protein Kinases: A. J. Bridges, Chem. Rev. 2001, 101, 2541-2571.

-Fragment-based lead discovery: D. C. Rees, M. Congreeve, W. Murray, R. Carr, Nature Rev. Drug Disc. 2004, 3,660-72

-Persuing the leadlikeness concept in pharmaceutical research: M. M. Hann, T. I. Oprea, Curr. Opin. Chem. Biol.2004, 8, 255-63.

-Design and synthesis of of protein superfamily-targeted chemical lbraries for lead identification and optimization,S. J. Shuttleworth, R. V. Connors, J. Fu, J. Liu, M. E. Lizarzaburu, W. Qiu, R. Sharma, M. Wanska, A. J. Zhang,Curr. Med. Chem. 2005, 12, 1239-81.

-Receptor-assisted Combinatorial Chemistry: Thermodynamics and Kinetics in Drug Discovery,J. D. Cheeseman, A. D. Corbett, J. L. Gleeson, and R. J. Katlauskas, Chem. Eur. J. 2005, 11, 1708-16.

-A decade of fragment-based drug design: Strategic advances and lessons learned,P. Hayduk, J. Greer, Nature Rev. Drug Disc. 2007, 6, 211-19.


4. Appendix-Reviews


-High throughput Lead Optimization in Drug Discovery; Ed. T.Kshirsagar,CRC Press, Taylo&Francis Group,2008.

-Discovery of innovative small molecule therapies; M. Abou-Garbia, J. Med. Chem. 2009, 52, 2-9.

-Transforming fragments into candidates; D. E. De Kloe et al. Drug Discov. Today 2009, 14, 630-646.

Documents

Medicinal Chemistry 09 - UZH - Department of · PDF filewinter semester 09 Daniel Obrecht, Polyphor Ltd 1 Agenda Medicinal Chemistry: Combinatorial Chemistry-Parallel Synthesis 1